Indoor residual spraying for preventing malaria in communities using insecticide-treated nets (Review)

Choi L, Pryce J, Garner P

Choi L, Pryce J, Garner P.
Indoor residual spraying for preventing malaria in communities using insecticide-treated nets.
Cochrane Database of Systematic Reviews 2019, Issue 5. Art. No.: CD012688.
DOI: 10.1002/14651858.CD012688.pub2.

www.cochranelibrary.com
## TABLE OF CONTENTS

- HEADER .................................................................................................................. 1
- ABSTRACT ................................................................................................................. 1
- PLAIN LANGUAGE SUMMARY ................................................................................. 2
- SUMMARY OF FINDINGS FOR THE MAIN COMPARISON .................................... 4
- BACKGROUND ........................................................................................................ 6
- OBJECTIVES ........................................................................................................... 7
- METHODS ............................................................................................................... 7
  - Figure 1. ................................................................................................................. 9
- RESULTS .................................................................................................................. 12
  - Figure 2. ................................................................................................................. 15
- ADDITIONAL SUMMARY OF FINDINGS ................................................................. 19
- DISCUSSION .......................................................................................................... 22
- AUTHORS' CONCLUSIONS .................................................................................... 23
- ACKNOWLEDGEMENTS ......................................................................................... 23
- REFERENCES ......................................................................................................... 24
- CHARACTERISTICS OF STUDIES ........................................................................ 28
- DATA AND ANALYSES .......................................................................................... 54
  - Analysis 1.1. Comparison 1 Non-pyrethroid-like indoor residual spraying (IRS) plus insecticide-treated nets (ITNs) versus ITNs alone, Outcome 1 Malaria incidence. ................................................................................................................. 55
  - Analysis 1.2. Comparison 1 Non-pyrethroid-like indoor residual spraying (IRS) plus insecticide-treated nets (ITNs) versus ITNs alone, Outcome 2 Malaria parasite prevalence. ................................................................................................................. 56
  - Analysis 1.3. Comparison 1 Non-pyrethroid-like indoor residual spraying (IRS) plus insecticide-treated nets (ITNs) versus ITNs alone, Outcome 3 Malaria parasite prevalence (net usage subgroup analysis). ................................................................................................................. 57
  - Analysis 1.4. Comparison 1 Non-pyrethroid-like indoor residual spraying (IRS) plus insecticide-treated nets (ITNs) versus ITNs alone, Outcome 4 Anaemia prevalence. ................................................................................................................. 58
  - Analysis 1.5. Comparison 1 Non-pyrethroid-like indoor residual spraying (IRS) plus insecticide-treated nets (ITNs) versus ITNs alone, Outcome 5 kdr allelic frequency. ................................................................................................................. 59
  - Analysis 2.1. Comparison 2 Pyrethroid-like indoor residual spraying (IRS) plus insecticide-treated nets (ITNs) versus ITNs alone, Outcome 1 Malaria incidence. ................................................................................................................. 60
  - Analysis 2.2. Comparison 2 Pyrethroid-like indoor residual spraying (IRS) plus insecticide-treated nets (ITNs) versus ITNs alone, Outcome 2 Malaria parasite prevalence. ................................................................................................................. 60
  - Analysis 2.3. Comparison 2 Pyrethroid-like indoor residual spraying (IRS) plus insecticide-treated nets (ITNs) versus ITNs alone, Outcome 3 Anaemia prevalence. ................................................................................................................. 61
- ADDITIONAL TABLES .............................................................................................. 61
- APPENDICES .......................................................................................................... 71
- CONTRIBUTIONS OF AUTHORS ............................................................................ 73
- DECLARATIONS OF INTEREST .............................................................................. 73
- SOURCES OF SUPPORT ........................................................................................ 74
- DIFFERENCES BETWEEN PROTOCOL AND REVIEW ......................................... 74
ABSTRACT

Background

Insecticide-treated nets (ITNs) and indoor residual spraying (IRS) are used to control malaria vectors. Both strategies use insecticides to kill mosquitoes that bite and rest indoors. For ITNs, the World Health Organization (WHO) only recommended pyrethroids until 2018, but mosquito vectors are becoming resistant to this insecticide. For IRS, a range of insecticides are recommended. Adding IRS to ITNs may improve control, simply because two interventions may be better than one; it may improve malaria control where ITNs are failing due to pyrethroid resistance; and it may slow the emergence and spread of pyrethroid resistance.

Objectives

To summarize the effect on malaria of additionally implementing IRS, using non-pyrethroid-like or pyrethroid-like insecticides, in communities currently using ITNs.

Search methods

We searched the Cochrane Infectious Diseases Group Specialized Register; the Cochrane Central Register of Controlled Trials (CENTRAL); MEDLINE; Embase; LILACS; the WHO International Clinical Trials Registry Platform; ClinicalTrials.gov; and the ISRCTN registry up to 18 March 2019.

Selection criteria

Cluster-randomized controlled trials (cRCTs), interrupted time series (ITS), or controlled before-and-after studies (CBAs) comparing IRS plus ITNs with ITNs alone.

Data collection and analysis

Two review authors independently assessed trials for eligibility, analyzed risk of bias, and extracted data. We used risk ratio (RR) and 95% confidence intervals (CI). We stratified by type of insecticide: 'non-pyrethroid-like', as this could improve malaria control better than adding IRS insecticides that have the same way of working as the insecticide on ITNs ('pyrethroid-like'). We used subgroup analysis of ITN usage in the trials to explore heterogeneity. We assessed the certainty of evidence using the GRADE approach.
Main results

Six cRCTs (eight comparisons) met our inclusion criteria conducted since 2008 in sub-Saharan Africa. Malaria transmission in all sites was from mosquitoes belonging to the *Anopheles gambiae* s.l. complex species; two trials in Benin and Tanzania also reported the vector *Anopheles funestus*. Three trials used insecticide with targets different to pyrethroids (two used bendiocarb and one used pirimiphos-methyl); two trials used dichloro-diphenyl-trichlorethane (DDT), an insecticide with the same target as pyrethroids; and one trial used both types of insecticide (pyrethroid deltamethrin in the first year, switching to bendiocarb for the second-year). ITN usage was greater than 50% in three trials, and less than 50% in the remainder.

**Indoor residual spraying using 'non-pyrethroid-like' insecticides**

Adding IRS with a non-pyrethroid-like insecticide had mixed results. Overall, we do not know if the addition of IRS impacted on malaria incidence (rate ratio 0.93, 95% CI 0.46 to 1.86; 2 cRCTs, 566 child-years; very low-certainty evidence); it may have reduced malaria parasite prevalence (0.67, 95% CI 0.35 to 1.28; 5 comparisons from 4 cRCTs, 10,440 participants; low-certainty evidence); and it may have reduced the prevalence of anaemia (RR CI 0.46, 95% 0.18 to 1.20; 3 comparisons from 2 cRCTs, 2026 participants; low-certainty evidence). Three trials reported the impact on EIR, with variable results; overall, we do not know if IRS had any effect on the EIR in communities using ITNs (very low-certainty evidence). Trials also reported the adult mosquito density and the sporozoite rate, but we could not summarize or pool these entomological outcomes due to unreported data. ITN usage did not explain the variation in malaria outcomes between different studies. One trial reported no effect on malaria incidence or parasite prevalence in the first year, when the insecticide used for IRS had the same target as pyrethroids, but showed an effect on both outcomes in the second year, when the insecticide was replaced by one with a different target.

Two trials measured the prevalence of pyrethroid resistance before and after IRS being introduced: no difference was detected, but these data are limited.

**Indoor residual spraying using 'pyrethroid-like' insecticides**

Adding IRS using a pyrethroid-like insecticide did not appear to markedly alter malaria incidence (rate ratio 1.07, 95% CI 0.80 to 1.43; 2 cRCTs, 15,717 child-years; moderate-certainty evidence), parasite prevalence (RR 1.11, 95% CI 0.86 to 1.44; 3 cRCTs, 10,820 participants; moderate-certainty evidence), or anaemia prevalence (RR 1.12, 95% CI 0.89 to 1.40; 1 cRCT, 4186 participants; low-certainty evidence). Data on the entomological inoculation rate (EIR) were limited, and therefore we do not know if IRS had any effect on the EIR in communities using ITNs (very low-certainty evidence).

**Authors’ conclusions**

Four trials have evaluated adding IRS using 'non-pyrethroid-like' insecticides in communities using ITNs. Some of these trials showed effects, and others did not. Three trials have evaluated adding IRS using 'pyrethroid-like' insecticides in communities using ITNs, and these studies did not detect an additional effect of the IRS. Given the wide geographical variety of malaria endemicities, transmission patterns, and insecticide resistance, we need to be cautious with inferences to policy from the limited number of trials conducted to date, and to develop relevant further research to inform decisions.

**PLAIN LANGUAGE SUMMARY**

Adding indoor residual spraying in communities using insecticide-treated nets for the prevention of malaria

What was the aim of this review?

Indoor residual spraying (IRS) is the regular application of chemical insecticides to household walls. The insecticide lasts for at least four months, killing mosquitoes that land on them. Insecticide-treated nets (ITNs) are bed nets treated with insecticides, preventing mosquitoes from biting people and reducing the mosquito population. Both interventions help to control malaria by reducing the number of people being bitten by mosquitoes infected with malaria. Implementing IRS in communities that are using ITNs may be better for malaria control than using ITNs alone for three reasons: two interventions may be better than one; it may improve malaria control where mosquitoes have become resistant to the pyrethroid insecticides used in ITNs; and the combination of ITNs and IRS may also help to slow the emergence of pyrethroid resistance (where pyrethroids are no longer effective at killing mosquitoes).

Pyrethroids were the only class of insecticides approved for use in ITNs until 2018, but growing resistance to pyrethroids impairs their effectiveness. The addition of IRS could counteract this reduction in ITN effectiveness. We could expect that IRS insecticides that
have a different way of working to pyrethroids (‘non-pyrethroid-like’) could restore effectiveness better than those that have the same way of working (‘pyrethroid-like’). The aim of this review was to summarize the impact of pyrethroid-like or non-pyrethroid-like IRS on malaria, when implemented in communities that are using ITNs.

**Key messages**

When IRS was conducted with a non-pyrethroid-like insecticide, some studies and outcomes suggested an impact, but this was not consistent. Factors such as the number of people using nets did not explain the differences between studies. When a pyrethroid-like insecticide was used for IRS, data were limited but there was no additional effect demonstrated.

**What was studied in the review?**

We searched for trials that evaluated the impact on malaria transmission when IRS, using a World Health Organization (WHO)-recommended dosage, was implemented in communities that were using either ready-treated ITN products or standard nets treated with insecticide at a WHO-recommended dose. We considered effects on both human health outcomes and on mosquito populations.

**What were the main results of the review?**

In total, we identified six trials matching our inclusion criteria, from which eight comparisons were drawn. Three trials (providing four comparisons) used a non-pyrethroid-like IRS throughout the study, and two trials (providing two comparisons) used a pyrethroid-like IRS throughout. One further trial used a pyrethroid-like IRS in the first study year and switched to a non-pyrethroid-like IRS in the subsequent years, therefore providing two different comparisons. All six trials were conducted in sub-Saharan Africa.

Adding non-pyrethroid-like IRS in communities using ITNs gave mixed results, with some trials detecting substantial effects but one trial detecting no effect. Overall, the results from the four included trials found that there may be a reduction in malaria parasite prevalence and anaemia prevalence (low-certainty evidence). We do not know if there is an impact on the malaria incidence or on the number of infected bites received per person per year (very low-certainty evidence).

When adding pyrethroid-like IRS in communities using ITNs, the data from three trials indicate there is probably no effect on malaria incidence or parasite prevalence (moderate-certainty evidence), and there may be little or no effect on the prevalence of anaemia. Data on the number of infected bites received per person per year were too limited to draw a conclusion (very low-certainty evidence).

**How up to date is the review?**

We searched for relevant trials up to 18 March 2019.
### Summary of Findings for the Main Comparison

**Non-pyrethroid-like indoor residual spraying (IRS) + insecticide-treated nets (ITNs) versus ITNs alone for preventing malaria**

**Patient or population:** people at risk of malaria  
**Setting:** sub-Saharan Africa (Benin, Tanzania, Sudan)  
**Intervention:** combination of IRS + ITNs - using an insecticide for IRS that has a different target site to the pyrethroids used in ITNs  
**Comparison:** ITNs alone

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Anticipated absolute effects* (95% CI)</th>
<th>Relative effect (95% CI)</th>
<th>Number of participants (studies)</th>
<th>Certainty of the evidence (GRADE)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Risk with ITNs alone</td>
<td>Risk with IRS + ITNs</td>
<td>Rate ratio</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Malaria incidence</td>
<td>317 cases per 1000 child-years</td>
<td>294 cases per 1000 child-years</td>
<td>Rate ratio 0.93 (0.46 to 1.86)</td>
<td>566 child-years (2 comparisons, 2 cRCTs)</td>
<td>⊕⊕⊕⊕ Very low&lt;sup&gt;a,b&lt;/sup&gt;</td>
</tr>
<tr>
<td>Malaria parasite prevalence</td>
<td>23.8 cases per 100</td>
<td>15.9 cases per 100 (8.3 to 30.4)</td>
<td>RR 0.67 (0.35 to 1.28)</td>
<td>10,440 participants (5 comparisons, 4 cRCTs)</td>
<td>⊕⊕⊕ Low&lt;sup&gt;a,c&lt;/sup&gt;</td>
</tr>
<tr>
<td>EIR</td>
<td>-</td>
<td>-</td>
<td>Mean EIR was lower with IRS in 2 of the 3 trials.</td>
<td>3</td>
<td>⊕⊕⊕ Very low&lt;sup&gt;c,f&lt;/sup&gt;</td>
</tr>
<tr>
<td>Anaemia prevalence</td>
<td>4.7 cases per 100</td>
<td>2.1 cases per 100 (0.0 to 5.7)</td>
<td>RR 0.46 (0.18 to 1.20)</td>
<td>2026 participants (3 comparisons, 2 cRCTs)</td>
<td>⊕⊕⊕ Low&lt;sup&gt;a,c&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

*We do not know if there is an effect on malaria incidence compared to ITNs alone.*

*May sometimes have reduced malaria parasite prevalence compared to ITNs alone.*

*We did not know if there was an effect on the EIR compared to ITNs alone.*

*May have reduced anaemia prevalence compared to ITNs alone.*
The risk in the intervention arm (and its 95% CI) is based on the assumed risk in the comparison arm and the relative effect of the intervention (and its 95% CI). The assumed risk of the comparison arm is calculated from the total number of events/total number of participants in the control arms of the trials contributing to the meta-analysis CI: confidence interval; cRCT: cluster randomized controlled trial; EIR: entomological inoculation rate; IRS: indoor residual spraying; ITN: insecticide-treated net; RR: risk ratio.

GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.
Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.

a Downgraded one level for serious imprecision: the CIs were wide and included both substantive increases and decreases in the outcome.
b Downgraded two levels for very serious inconsistency: there were two trials in the subgroup, reporting directly contrasting effects. This was represented by the I² value of 84% within the subgroup.
c Downgraded one level for serious inconsistency: three trials demonstrated an effect and one trial did not. Consequently, there was considerable qualitative heterogeneity with an I² value of 86% within the subgroup.
d Downgraded one level for serious inconsistency: large differences in effect estimates were reported in the three studies.
e Downgraded one level for serious inconsistency: there was moderate heterogeneity with an I² value of 41% within the subgroup. One study reported a substantial reduction in anaemia and another reported a moderate reduction. One comparison in the subgroup showed no effect by adding IRS, though it should be noted this comparison assessed the addition of IRS to pyrethroid-piperonyl butoxide nets.
f Downgraded two levels for very serious imprecision: where provided, the CIs for the mean EIR in the intervention arms were very wide, including values that would represent both large increases and reductions from the mean EIR in the control arms. The trial showing the greatest reduction in EIR did not report CIs for this outcome and it is, therefore, difficult to assess the precision (Protopopoff 2018).
BACKGROUND

Description of the condition

Between 2000 and 2015, malaria deaths halved globally. In this time, malaria control interventions were estimated to have averted 663 million cases of malaria, with much of the progress considered to be due to improved vector control (Bhatt 2015). Despite this decline, the disease is still a leading cause of mortality, responsible for 445,000 deaths worldwide in 2016 (WHO 2017a).

Description of the intervention

Vector control depends largely on insecticides, primarily delivered as indoor residual spraying (IRS) or insecticide-treated nets (ITNs). IRS is the regular spraying of insecticides to the indoor walls of houses. The insecticide lasts for at least four months, killing mosquitoes that land on it. ITNs are bed nets treated with insecticides, preventing mosquitoes from biting people and reducing the mosquito population. ITNs include long-lasting insecticidal nets (LLINs), where the insecticide lasts for up to three years, and conventionally treated nets, where the insecticide is active for up to 12 months. Up until 2018, only pyrethroid class insecticides were considered safe enough to be used for ITNs (Zaim 2000). However, the non-insecticide chemical piperonyl butoxide (PBO) can also be added to ITNs, making them more effective at killing mosquitoes in areas where the mosquito populations are highly resistant to pyrethroids (Gleave 2018). Insecticides used for IRS are less restricted, as people living in the households are considered less likely to come into contact with the treated walls than with the fabric of a bed net.

Pyrethroids target the mosquito voltage-gated sodium ion channels. If mosquito resistance to pyrethroids is leading to reduced effectiveness of ITNs, IRS using insecticides with different target sites (‘non-pyrethroid-like’ insecticides) may be less affected by the pyrethroid resistance and more likely to have an impact on malaria transmission. In contrast, IRS using insecticides that also target the voltage-gated sodium ion channels (‘pyrethroid-like’ insecticides) may be less likely to have an impact.

How the intervention might work

IRS with dichloro-diphenyl-trichloroethane (DDT) was the main intervention of the malaria eradication programmes in the mid-20th century (Pluess 2010). When malaria was eliminated from many parts of South America, Europe, and Asia, IRS was an integral part of the elimination strategies (Pluess 2010). However, many countries today choose to adopt ITNs rather than IRS, as they are logistically easier to implement than IRS and more acceptable to communities. Theoretically, the simultaneous use of IRS and ITNs is better for malaria control than using ITNs alone for three reasons. First, we might expect an incremental effect of using two vector control interventions over one, particularly when the target vector species both feeds and rests indoors (endophagic and endophilic vectors). As with many vector control interventions, the reality is not simple and the success of the intervention will depend on both human and vector behaviour (Killeen 2006). Mosquito exophily can reduce the effectiveness of IRS and ITNs, as mosquitoes that rest outdoors more will have less contact with an indoor treated wall or net (Kitau 2012). Earlier biting times of Anopheles spp have also been observed, which can increase the likelihood of a mosquito encountering a human to bite and reduce the impact of ITNs (Ojuka 2015).

Second, implementing IRS in communities currently using ITNs may be beneficial for the management of mosquito resistance to insecticides. Malaria control programmes may additionally implement IRS as a reactive measure in response to high pyrethroid resistance in Anopheles mosquitoes. The addition of IRS, particularly with non-pyrethroid-like insecticides, could mitigate for this reduction in ITN effectiveness.

Third, policy-makers could also introduce a combination of the two interventions proactively, administering a non-pyrethroid-like IRS alongside ITNs as part of an insecticide resistance management (IRM) strategy to delay the emergence of pyrethroid resistance (WHO 2012).

Why it is important to do this review

The combination of IRS and ITNs can be logistically complicated to deliver. ITNs are advantageous because they can last for three to five years, and because net distribution campaigns can be conducted at a village central point or community health centre. In contrast, the current set of insecticides used for IRS will remain active for six months at best, and an effective spray campaign in a setting with perennial malaria transmission will therefore require several sprays per year (WHO 2015a). IRS is also logistically more demanding, requiring a visit to every individual household. IRS programmes typically take a substantially higher amount of financial commitment than an ITN distribution campaign, in part due to the sheer quantity of insecticide required at programmatic scales (Goodman 2001). Finally, IRS has experienced more problems with the acceptability of the intervention and its delivery than ITNs (Kleinschmidt 2009).

Advice has changed over time about whether or when the combination of IRS and ITNs should be used. In the past, the Global Technical Strategy has recommended combining ITNs with IRS for epidemic situations only (WHO 2015b). The current WHO Elimination Framework continues to recommend that elimination programmes using ITNs as a core strategy maintain a capacity to conduct IRS for the rapid clearance of transmission foci (WHO 2017b). However, it additionally recommends IRS is applied as a...
resistance management strategy in areas where ITNs are the primary intervention and vectors are resistant to pyrethroids. It is recommended that IRS is applied in a rotation of different classes of insecticide, though there is some ambiguity over when rotations should be carried out. The framework also guides that IRS should not be used to compensate for poor coverage of ITNs.

In the past few years, the effect of combining IRS with ITNs has been contentious, with inconsistent results reported across different trials. Modelling data has even suggested an antagonistic effect of combining IRS with ITNs when ITN coverage is poor (Yakob 2011). A greater understanding of the effect on malaria transmission is required to determine whether the additional logistical complexity of combining IRS with ITNs is worthwhile.

OBJECTIVES
To summarize the effect on malaria of additionally implementing IRS, using non-pyrethroid-like or pyrethroid-like insecticides, in communities currently using ITNs.

METHODS

Criteria for considering studies for this review

Types of studies
- Randomized controlled trials (RCTs) with: the unit of randomization being a cluster and at least two clusters per arm (cRCTs). As the two interventions were distributed at a community level, we did not expect to find trials with individual randomization.
- Controlled before-and-after studies (CBAs) with: a contemporaneous control arm and at least two sites per arm.
- Interrupted time series designs (ITS) with: a clearly defined point in time when the intervention occurred and at least three data points before and three after the intervention.

Types of participants
All people living in a rural or urban malarious area where ITNs are in use. We included participants living in all levels of endemicity, including both stable and unstable transmission.

Types of interventions
IRS using the World Health Organization (WHO)-recommended dosage (see Table 1; WHO 2015a). We individually evaluated the effects of IRS using:

- ‘non-pyrethroid-like insecticides’: those with alternative targets such as acetylcholinesterase, in contrast to ITNs.
- ‘pyrethroid-like insecticides’: those that target the voltage-gated sodium ion channels, similarly to ITNs.

ITNs interventions were required to be the same in both intervention and control arms. Suitable ITNs included LLINs and pyrethroid-PBO nets, with either a full or preliminary recommendation by the WHO (Table 2), or conventionally treated nets, treated with insecticide at the WHO-recommended dosage (Table 3).

Any other malaria control measures were required to be the same in both intervention and control arms.

Types of outcome measures

Primary outcomes
Studies eligible for inclusion must have reported at least one of the following.
- Malaria incidence: measured as a count per person unit time of (a) infections or (b) new infections, following treatment to avoid measuring pre-existing infections. Infection was defined as any symptom, including fever, with confirmed parasitaemia (by blood smear microscopy or rapid diagnostic test (RDT)).
- Malaria parasite prevalence: the proportion of surveyed people with confirmed parasitaemia.

Secondary outcomes

Entomological
- Entomological inoculation rate (EIR): the estimated number of bites by infectious mosquitoes per person per unit of time. This was measured using the human biting rate (the number of mosquitoes biting a person over a stated period measured directly using human baits or indirectly using light traps, knock-down catches, baited huts, or other methods of biting rate determination) multiplied by the sporozoite rate.
- Sporozoite rate: the fraction of vector mosquitoes present and biting that were considered infectious, measured by a technique previously shown to be appropriate for the vector (microscopy, immunoassays, polymerase chain reaction-based assays or other methods).
- Adult mosquito density: measured by a technique previously shown to be appropriate for the vector (human baits, light traps, knock-down catches, baited huts, or other methods).
Epidemiological

- Malaria-related deaths.
- Anaemia prevalence defined as per WHO cut-offs (WHO 2011).
- Hospital admissions for malaria.
- Number of people with severe malaria: using site-specific definitions, provided they included (a) and either (b) or (c): (a) demonstration of parasitaemia by blood smear; (b) symptoms of cerebral malaria including coma, prostration or multiple seizures; (c) severe, life-threatening anaemia (WHO 2015c).
- Number of people with uncomplicated clinical malaria episodes: we will use site-specific definitions, provided they include: (a) demonstration of malaria parasites by blood smear or an RDT, or both; and (b) clinical symptoms including fever detected passively or actively.

Mosquito insecticide resistance

- Level of insecticide resistance, confirmed by WHO cylinder assays/ Centers for Disease Control and Prevention (CDC) bottle bioassays or molecular techniques. This included resistance to either the class of insecticide used for IRS (that is, as an unwanted outcome of trials due to increased coverage of insecticidal interventions) or to pyrethroid insecticides (to monitor whether the addition of IRS prevented or reduced resistance to ITNs).

Search methods for identification of studies

We attempted to identify all relevant trials regardless of language or publication status (published, unpublished, in press, and in progress).

Electronic searches

We searched the following databases up to 18 March 2019 using the search terms and strategy described in Appendix 1: Cochrane Infectious Diseases Group Specialized Register; Cochrane Central Register of Controlled Trials (CENTRAL) Issue 3, April 2019, published in the Cochrane Library; MEDLINE (PubMed); Embase (Ovid); and LILACS (Bireme). We also checked the WHO International Clinical Trials Registry Platform (WHO ICTRP; www.who.int/ictrp/en/) and ClinicalTrials.gov (clinicaltrials.gov/ct2/home) for ongoing trials, also on 18 March 2019, using the terms: indoor residual spraying; IRS; insecticide-treated nets; bednets; ITNs; LLIN.

Searching other resources

We contacted researchers working in the field for unpublished data. We also checked the reference lists of all trials identified by the above methods.

Data collection and analysis

Selection of studies

Two review authors (LC and JP) independently assessed the titles and abstracts of trials identified by the searches. The same two review authors assessed full-text copies of potentially relevant trials for inclusion using an eligibility form based on the inclusion criteria. We compared the results of our assessments and resolved any disagreements by discussion and consensus, with arbitration by a third review author (PG) when necessary. We ensured that multiple publications of the same trial were included once. We listed excluded studies, together with their reasons for exclusion, in the Characteristics of excluded studies table. We illustrated the study selection process in a PRISMA diagram (Figure 1).
Figure 1. Study flow diagram.

- 998 records identified through database searching
- 997 records after duplicates removed
- 997 records screened
- 961 records excluded
- 36 full-text articles assessed for eligibility
- 18 full-text articles excluded for wrong study design
- 8 full-text articles excluded for being duplicates
- 4 full-text articles described 3 studies awaiting classification
- 6 studies included in qualitative synthesis
- 6 studies included in quantitative synthesis (meta-analysis)
Data extraction and management
Two review authors (LC and JP) independently extracted information from the trials using prepiloted, electronic data extraction forms. In case of differences in extracted data, the two review authors discussed these differences to reach consensus. If unresolved, we contacted a third review author (PG). In case of missing data, we contacted the original study author(s) for clarification.
We extracted data on the following.
- Trial design: type of trial; method of participant selection; adjustment for clustering (for cRCTs); sample size; method of blinding of participants and personnel.
- Participants: trial settings and population characteristics; recruitment rates; withdrawal and loss to follow-up.
- Intervention: description of intervention and control (active ingredient, dose, formulation, method, frequency and timing of application, buffer zone between clusters); cointerventions; description of control; coverage of intervention, control, and cointerventions; compliance of intervention, control, and cointerventions.
- Outcomes: definition of outcome; diagnostic method or surveillance method; passive or active case detection; duration of follow-up; time points at which outcomes were assessed; number of events; number of participants or unit time; statistical power; unit of analysis; incomplete outcomes/missing data.
- Other:
  - primary and secondary vector(s) species; vector(s) behaviour (nature, stability, adult habitat, peak biting times, exophilic/endophilic, exophagic/endophagic, anthropophilic/zoophilic); method of mosquito collection(s); phenotypic insecticide resistance (based on WHO definitions if supplementary WHO cylinder assays or CDC bottle bioassays, or both, were performed while the trial was running); genotypic insecticide resistance profile (either performed during the trial or if the trial referenced data from previous studies done on the same local vector population within the previous five years);
  - malaria endemicity; eco-epidemiological setting; human population proximity to mosquito aquatic habitats; human population density per area; Plasmodium spp.

For dichotomous outcomes, we extracted the number of participants experiencing each outcome and the number of participants in each treatment arm. For count/rate data outcomes, we extracted the number of outcomes in the treatment and control arms, and the total person time at risk in each arm or the rate ratio, and a measure of variance (for example, standard error). For continuous outcomes, we extracted the mean and a measure of variance (standard deviation).

For cRCTs, we recorded the number of clusters randomized; number of clusters analyzed; measure of effect (such as risk ratio (RR), odds ratio, or mean difference (MD)) with 95% confidence intervals (CI) or standard deviations; number of participants; and the intracluster correlation coefficient (ICC) value. Where trials reported cluster-adjusted odds ratios, we converted these to RRs following the methodology stated in Section 12.5.4.4 of the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011a).

For non-randomized studies, we extracted adjusted measures of intervention effects that attempted to control for confounding.

Assessment of risk of bias in included studies
Two review authors (LC and JP) independently assessed the risk of bias for each included cRCT using the Cochrane ‘Risk of bias’ tool and the five additional criteria listed in Section 16.3.2 of the Cochrane Handbook for Systematic Reviews of Interventions that relate specifically to cluster-randomized trials (Higgins 2011a; Higgins 2011b). If identified, we would have assessed non-RCTs and ITS trials for risk of bias using Cochrane EPOC’s ‘Risk of bias’ tool. We resolved any discrepancies through discussion or by consulting a third review author (PG). We classified judgements of risk of bias as low, high, or unclear risk of bias, and we used summary graphs (‘Risk of bias’ summary and ‘Risk of bias’ graph) to display results.

Due to the nature of the IRS application, blinding of participants and study personnel was not possible. When assessing the risk of performance bias, we considered that the primary outcomes of malaria incidence and malaria parasite prevalence were unlikely to be affected by participant knowledge of the intervention. Therefore, we did not associate the lack of participant blinding with a high risk of performance bias. When assessing the risk of detection bias, we considered that measurements of incidence that depended on self-reporting of fever may have been influenced by the participants’ knowledge of the intervention. However, to meet the inclusion criteria for this review, such cases required confirmation of parasitaemia by blood smear microscopy or RDT, and the results of these objective tests were considered unlikely to be influenced by knowledge of the intervention arm. Therefore, where trials measured incidence using this method, we considered the lack of blinding to introduce an unclear risk of bias; this is consistent with the methods used by Pryce 2018.

Measures of treatment effect
We compared intervention and control data using RRs and for count/rate data, we used rate ratios. We used adjusted measures of effect to summarize treatment effect from non-randomized studies. We presented all results with their associated 95% CIs.
Unit of analysis issues
For cRCTs, or cluster non-randomized trials, we extracted adjusted measures of effect where possible. If included cRCTs had not adjusted for clustering in the analysis, we adjusted the data before combining it. We adjusted data by multiplying the standard errors by the square root of the design effect (Higgins 2011a), which was determined by the ICC. If the trial did not report the ICC value, we estimated the ICC value using a range of 0.01, 0.05, and 0.1. When we estimated the ICC, we performed sensitivity analyses to investigate the robustness of our analyses. If we identified studies for inclusion that had multiple intervention arms, we included data from these studies by either combining treatment arms, or by splitting the control arm so that we only included these participants in the meta-analysis once.

Dealing with missing data
In case of missing data, we applied available-case analysis, only including data on the known results. The denominator was the total number of participants who had data recorded for the specific outcome. For outcomes with no missing data, we planned to perform analyses on an intention-to-treat basis. We included all participants randomized to each arm in the analyses and analyzed participants in the arm to which they were randomized.

Assessment of heterogeneity
We inspected forest plots for overlapping CIs and assessed statistical heterogeneity in each meta-analysis using the I² statistic and Chi² statistic. We regarded heterogeneity as moderate if the I² statistic was between 30% and 60%; substantial if it was between 50% and 90%; and considerable if it was between 75% and 100% (Deeks 2011). We regarded a Chi² test statistic with a P value less than 0.10 indicative of statistically significant heterogeneity. We explored clinical and methodological heterogeneity through consideration of the trial populations, methods, and interventions, and by visualization of trial results.

Assessment of reporting biases
If there were 10 or more trials included in each meta-analysis, we intended to investigate reporting biases (such as publication bias) using funnel plots. We would have assessed funnel plot asymmetry visually, and used formal tests for funnel plot asymmetry (Harbord 2006). If we detected asymmetry in any of these tests or by a visual assessment, we would have explored the reasons for asymmetry. As only six trials met the inclusion criteria, we did not investigate reporting bias using a funnel plot. Instead, we compared the outcomes reported against the trial protocols.

Data synthesis
We analyzed data using Review Manager 5 (Review Manager 2014). We used fixed-effect meta-analysis to combine data if heterogeneity was absent. For a meta-analysis of reported effect sizes, we used a generalized inverse variance model. Where raw data were used for a meta-analysis of RRs, we used a Mantel-Haenszel model. For meta-analysis of RRs and odds ratios, if considerable heterogeneity was present, we combined data using random-effects meta-analysis and reported a mean treatment effect. We decided whether to use fixed-effect or random-effects models based on the consideration of clinical and methodological heterogeneity between trials, as described previously.

Certainty of the evidence
We assessed the certainty of the evidence using the GRADE approach (Guyatt 2011). We rated each important outcome as described by Balshem 2011.

• High: we are very confident that the true effect lies close to that of the estimate of the effect.
• Moderate: we are moderately confident in the effect estimate. The true effect is likely to be close to the estimate of the effect.
• Low: our confidence in the effect estimate is limited. The true effect may be substantially different from the estimate of the effect.
• Very low: we have very little confidence in the effect estimate. The true effect is likely to be substantially different from the estimate of effect.

RCTs started as high-certainty evidence but were downgraded if there were valid reasons within the following five categories: risk of bias, imprecision, inconsistency, indirectness, and publication bias. Studies could also be upgraded if there was a large effect, a dose-response effect, and if all plausible residual confounding would reduce a demonstrated effect or would suggest a spurious effect if no effect was observed (Balshem 2011). We summarized our findings in Summary of findings for the main comparison and Summary of findings 2.

Subgroup analysis and investigation of heterogeneity
To explore reasons for substantial heterogeneity, we performed the following subgroup analysis.

• Use of ITNs, defined by individual use from the previous night:
  ○ high (50% or more);
  ○ low (less than 50%).

We assessed differences between the subgroups using the Chi² test, with a P value less than 0.1 indicating statistically significant differences between subgroups.
Sensitivity analysis

We planned to perform sensitivity analysis on the primary outcome to see the effect of exclusion of trials at high risk of bias (for allocation concealment and incomplete outcome data) on the overall results. This was not required since all studies included were at low or unclear risk of bias for those specific domains. If the ICC value was estimated, we did sensitivity analyses to investigate the impact of varying the ICC value on meta-analysis results.

RESULTS

Description of studies

We provided descriptions of the included and excluded studies in the Characteristics of included studies and Characteristics of excluded studies tables. Studies awaiting classification were described in the Characteristics of studies awaiting classification table.

Results of the search

We identified 998 reports through the electronic search. We removed one duplicate and screened the remaining 997 abstracts against the review’s inclusion criteria. Of these, we identified 36 unique reports for full-text screening (Figure 1).

Included studies

In total, six trials met the inclusion criteria, from which eight comparisons were drawn. All six trials were cRCTs. Three trials (providing four comparisons) used a non-pyrethroid-like IRS throughout the trial (Corbel 2012; Protopopoff 2018; West 2014), and two trials (providing two comparisons) used a pyrethroid-like IRS throughout (Keating 2011; Pinder 2015). One further trial used a pyrethroid-like insecticide in the first study year, but replaced it with a non-pyrethroid-like insecticide for the two subsequent years, and therefore provided two different comparisons (Kafy 2017).

Comparison 1: IRS using non-pyrethroid-like insecticides

The four trials evaluating the effect of non-pyrethroid-like IRS were conducted in sub-Saharan Africa; one in southern Benin (Corbel 2012); one in south-eastern Sudan (Kafy 2017), and two in north-west Tanzania (Protopopoff 2018; West 2014). The former two regions experience seasonal transmission, while north-west Tanzania has perennial transmission with two peak seasons. None of the trials were conducted in epidemic areas. Two trials evaluated the effect of adding IRS to ITNs using a two-armed study design (Kafy 2017; West 2014). Two trials had four arms. Corbel 2012 compared universal coverage of ITNs; universal coverage of ITNs plus carbamate-treated plastic sheeting; targeted ITNs (aiming only to cover pregnant women and children under six years old); and targeted ITNs plus IRS. The latter two arms provide the comparison for this review. Protopopoff 2018 used a 2 x 2 factorial design which compared standard LLINs; standard LLINs plus IRS; pyrethroid-PBO nets; and pyrethroid-PBO nets plus IRS.

Interventions

Coverage

IRS application coverage was described as 80% of households in the study area (Corbel 2012), consistently above 80% (Kafy 2017), 94% in both IRS intervention arms (Protopopoff 2018), and 89.3% to 92.1% (West 2014).

Insecticide

Two trials used a WP formulation of the carbamate bendiocarb, at a dose of 400 mg/m² (Corbel 2012; West 2014), and in the second year of another trial (Kafy 2017). Protopopoff 2018 used Actellic 300CS (a commercial formulation of pirimiphos-methyl), at a dosage of 1g/m².

Frequency

The frequency of spraying varied depending on the eco-epidemiological conditions of each location. Two trials conducted two rounds, four months apart, preceding each of two annual transmission peaks (Kafy 2017; West 2014). Corbel 2012 repeated the IRS cycle every eight months, and Protopopoff 2018 conducted only one spraying round. Full characteristics of the interventions are summarized in Table 4.

ITNs in intervention and control arms

In each of the trials, ITN distribution was equal between the intervention and control arms. In two trials, the ITN distributed was the deltamethrin-based PermaNet 2.0 (Corbel 2012; Kafy 2017), while two trials involved distribution of the permethrin-based Olyset Net (Protopopoff 2018; West 2014). In the two arms that evaluated the efficacy of pyrethroid-PBO nets, Protopopoff 2018 used Olyset Plus instead of Olyset Net. A measure of ITN coverage and compliance for each study is summarized in Table 5.
Cointerventions
The four trials did not report on any cointerventions.

Outcomes

Epidemiological
All four trials measured clinical outcomes in children only; one in those under six years of age (Corbel 2012), one in children aged one to 10 years of age (Kafy 2017), and two between six months and 14 years (Protopopoff 2018; West 2014). Of the two primary outcomes, malaria incidence was measured in two studies (Corbel 2012; Kafy 2017), and malaria parasite prevalence was measured in all four trials. Two trials also reported the prevalence of childhood anaemia (Protopopoff 2018; West 2014). Protopopoff 2018 limited their analysis of anaemia to children aged six months to four years. We extracted the nine-month postintervention cross-sectional survey results only, as IRS was not conducted beyond this time point, which acted as their main endpoint for assessing the efficacy of IRS (Protopopoff 2018).

Insecticide
Two trials used a wettable powder (WP) formulation of DDT, at a dose of 1 g/m² to 2 g/m² (Keating 2011; Pinder 2015). One trial used the pyrethroid deltamethrin at a dose of 25 mg/m² in the first study year (Kafy 2017).

Frequency
The frequency of spraying varied depending on the eco-epidemiological conditions of each location. One trial conducted IRS once per year to coincide with the start of the transmission season (Pinder 2015). One trial conducted two rounds, four months apart, preceding each of two annual transmission peaks (Kafy 2017). One trial conducted only one spraying round (Keating 2011). Full characteristics of the interventions have been summarized in Table 4.

Entomological
Three trials reported estimated EIR, adult mosquito density, and the sporozoite rate (Corbel 2012; Protopopoff 2018; West 2014).

Mosquito insecticide resistance
One trial additionally reported the prevalence in malaria vectors of alleles associated with resistance to pyrethroids (1014F kdr) and carbamates (G119S ace1) (Corbel 2012). Kafy 2017 reported the level of phenotypic resistance to pyrethroids.

Comparison 2: IRS using pyrethroid-like insecticides
The three cRCTs evaluating pyrethroid-like IRS were all conducted in sub-Saharan Africa; in the west lowlands of Eritrea (Keating 2011), the upper river region of The Gambia (Pinder 2015), and in south-eastern Sudan (Kafy 2017). The regions each experience seasonal transmission, and none were in epidemic areas.

Interventions

Coverage
IRS application coverage was described as consistently above 80% (Kafy 2017), 84.8% (Keating 2011), and 83% to 86% (Pinder 2015).

ITNs in intervention and control arms
In each of the three trials, ITN distribution was equal between the intervention and control arms. In one trial, the ITN distributed was the deltamethrin-based PermaNet 2.0 (Kafy 2017), while one trial involved distribution of the permethrin-based Olyset Net (Pinder 2015). One trial did not distribute ITNs as the region already had a high coverage; any LLIN, or ITN that had been treated at least once in the last 11 months, was considered acceptable when measuring net coverage in this study (Keating 2011). A measure of ITN coverage and compliance for each study is summarized in Table 5.

Cointerventions
One trial listed larval habitat management and continued case management as cointerventions that were conducted in both intervention and control arms during the study period (Keating 2011). The remaining trials did not report on any cointerventions.

Outcomes

Epidemiological
Two trials measured clinical outcomes in children only; one in children aged one to 10 years of age (Kafy 2017), and one in children aged one to 14 years of age (West 2014). Of the two primary outcomes, malaria incidence was measured in two studies (Corbel 2012; Kafy 2017), and malaria parasite prevalence was measured in all four trials. Two trials also reported the prevalence of childhood anaemia (Protopopoff 2018; West 2014). Protopopoff 2018 limited their analysis of anaemia to children aged six months to four years. We extracted the nine-month postintervention cross-sectional survey results only, as IRS was not conducted beyond this time point, which acted as their main endpoint for assessing the efficacy of IRS (Protopopoff 2018).
aged between six months and 14 years (Pinder 2015). The third trial measured outcomes in participants of all ages (Keating 2011). Of the two primary outcomes, two studies measured malaria incidence (Kafy 2017; Pinder 2015), and all three trials measured malaria parasite prevalence. One trial also reported the prevalence of childhood anaemia (Pinder 2015). For malaria parasite prevalence and anaemia prevalence, Pinder 2015 reported separately adjusted effect estimates for both years of the study, 2010 and 2011, so we included both estimates in the analysis separately.

**Excluded studies**

We excluded 26 full-text articles for the following reasons:

- study design did not meet the inclusion criteria (18 full-text articles);
- duplicate articles (eight full-text articles).

Full details are provided in the Characteristics of excluded studies tables.

**Studies awaiting classification**

Four full-text articles describing three studies are currently reported in the ‘Characteristics of studies awaiting classification’ table. One is a stepped wedge design and the results presented are not in a form that can be used in this analysis; we have requested additional data from the study authors (Hamainza 2016). The other two trials have been completed and we are awaiting publication of the results (Chaccour 2018; Deressa 2016).

**Risk of bias in included studies**

Trials overall were well designed with few concerns over risk of bias (Figure 2). Details of the assessment are included in the ‘Risk of bias’ table of the Characteristics of included studies table.

---

**Entomological**

One trial reported the estimated EIR, sporozoite rate, and adult mosquito density measured as the number of adult *An. gambiae*s.l. collected per trap per night (Pinder 2015).

**Mosquito insecticide resistance**

One trial measured the prevalence of alleles associated with pyrethroid resistance only (Kafy 2017).
Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included study.

<table>
<thead>
<tr>
<th>Study</th>
<th>Random sequence generation (selection bias)</th>
<th>Allocation concealment (selection bias)</th>
<th>Blinding of participants and personnel (performance bias)</th>
<th>Blinding of personnel assessment (performance bias)</th>
<th>Blinding of outcome assessment (detection bias)</th>
<th>Incomplete outcome data (attrition bias)</th>
<th>Selective reporting (reporting bias)</th>
<th>Recruitment bias</th>
<th>Baseline imbalance</th>
<th>Loss of clusters</th>
<th>Incorrect analysis</th>
<th>Comparability with RCTs randomizing participants</th>
</tr>
</thead>
<tbody>
<tr>
<td>Corbel 2012</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Kafy 2017</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Keating 2011</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Pinder 2015</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Protopopoff 2018</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>West 2014</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>
Allocation
We assessed five trials at low risk of bias for random sequence generation and allocation concealment, as allocation was decided using a computerized randomization algorithm (Corbel 2012; Kafy 2017; Pinder 2015; Protopopoff 2018; West 2014). One trial was at unclear risk of bias because the randomization procedure was not described (Keating 2011).

Blinding
Due to the nature of the IRS application, blinding of participants and study personnel was not possible. Participant and personnel knowledge of intervention arm was not expected to have an influence on the outcomes included in this review.

One trial blinded microscopists (Pinder 2015). However, all six trials measured prevalence using either a RDT or blood smear examination. As these tests are objective, all six trials were at low risk of detection bias. Two trials that measured malaria incidence depended on self-reporting of fever, and as such the detection of this outcome may have been influenced by the participants’ knowledge of the intervention (Corbel 2012; Pinder 2015). However, both cases confirmed para-itaemia using objective tests. Therefore, the trials were at unclear risk of bias. The remaining trial used active case detection with RDTs to measure incidence and was, therefore, considered at low risk of performance bias.

Incomplete outcome data
One trial reported a difference of more than 10% between the intervention and control arms in person-days that were lost to follow-up (Corbel 2012). This was judged at high risk of bias. The remaining five trials were at low (Keating 2011; Pinder 2015; Protopopoff 2018; West 2014) or unclear risk of bias (Kafy 2017).

Selective reporting
The trials reported on each of their intended outcomes as specified in their registered protocols.

Other potential sources of bias
None of the trials were considered at risk of recruitment bias as the study participants were randomly selected. One trial was at unclear risk of baseline imbalance, as the baseline data for prevalence were not reported (Keating 2011). No trials were at high or unclear risk of bias from loss of clusters, incorrect analyses, or other biases.

Effects of interventions
See: Summary of findings for the main comparison ‘Summary of findings’ table 1; Summary of findings 2 ‘Summary of findings’ table 2

Comparison 1: adding IRS using non-pyrethroid-like insecticides to ITNs
See Summary of findings for the main comparison.

Malaria incidence
Two trials reported malaria incidence (Corbel 2012; Kafy 2017). One trial reported a substantial benefit of IRS, while the other reported a higher malaria incidence in the intervention arm. This lack of consistency was reflected in the considerable heterogeneity (I² = 84%). As there are only two trials, a subgroup analysis by ITN usage would not be informative. Overall, the pooled analysis gave a mean effect between the two results (rate ratio 0.93, 95% CI 0.46 to 1.86; 2 cRCTs, 566 child-years; Analysis 1.1; very low-certainty evidence).

The results from Kafy 2017 were noteworthy: the data from different years of the trial appeared in both Comparison 1 and Comparison 2. The first year had shown the addition of IRS using a pyrethroid-like insecticide had no effect on malaria incidence (RR 1.00, 95% CI 0.36 to 2.78); in the second and third years, when a non-pyrethroid-like insecticide was used for IRS, there was a lower malaria incidence (RR 0.65, 95% CI 0.44 to 0.96).

Malaria parasite prevalence
All four trials assessed the effect on malaria parasite prevalence. One trial provided two comparisons to the analysis, one comparing standard ITNs plus IRS versus standard ITNs alone, and a second comparing pyrethroid-PBO nets plus IRS versus pyrethroid-PBO nets alone (Protopopoff 2018). In the comparison involving standard ITNs, the addition of IRS was associated with a large reduction in malaria parasite prevalence (RR 0.52, 95% CI 0.18 to 1.52). However, the effect was much less pronounced in the comparison involving pyrethroid-PBO nets (RR 0.85, 95% CI 0.34 to 2.11). This may be explained by the improved effectiveness of pyrethroid-PBO nets over standard ITNs seen in the study. Even in the absence of IRS, the pyrethroid-PBO net arm had a prevalence of 31%, compared to 55% in the standard ITN arm. Across the included studies, the pooled analysis showed the malaria parasite prevalence was lower when IRS was added (RR 0.67, 95% CI 0.35 to 1.28; 4 cRCTs, 10,440 participants; Analysis 1.2; low-certainty evidence). Most studies showed a benefit of IRS with substantial reductions in prevalence, but one study again reported...
a higher prevalence in the intervention arm (Corbel 2012). This lack of consistency is reflected in the considerable heterogeneity (I² = 86%). We conducted a subgroup analysis by percentage of the trial population sleeping under an ITN (Analysis 1.3). Two trials were conducted with ITN use below 50% (Corbel 2012; West 2014), and two were conducted with ITN use of 50% or more (Kafy 2017; Protopopoff 2018). This analysis did not explain the heterogeneity.

The results from Kafy 2017 were noteworthy: the data from different years of the trial appeared in both Comparison 1 and Comparison 2. In the first year, following IRS implementation using a pyrethroid-like insecticide, there was an increase in malaria parasite prevalence in the intervention arm (RR 1.96, 95% CI 0.86 to 4.46). However, in the second and third years, when a non-pyrethroid-like insecticide was used for IRS, there was a large reduction in prevalence (RR 0.41, 95% CI 0.28 to 0.61).

**Entomological inoculation rate**

Three trials reported estimates of the EIR (Corbel 2012; Protopopoff 2018; West 2014). Due to considerable differences between trials in the way the EIR was defined, estimated, and in the effect sizes reported, it was not possible to conduct a meta-analysis. We presented the results of each trial in Table 6.

In summary, the EIR was lower when IRS was added in one of the three trials. The results correlated with the reported epidemiological outcomes in two of the three trials.

- **Corbel 2012** reported a slightly lower mean value for the number of infected bites per person per year when IRS was added (7.3%, 95% CI 3.8 to 14.2) compared to the control arm (9.4, 95% CI 5.1 to 17.1). This was concordant with the results for epidemiological outcomes, where there was no evidence of a lower malaria incidence or parasite prevalence in the combined arm.

- **In both comparisons of Protopopoff 2018**, there was a much lower mean EIR when IRS was added to nets. Similarly to the above epidemiological outcomes, the lower EIR was more marked in the comparison with the standard ITNs; whereas the EIR in the ITN-only arm was much lower with the pyrethroid-PBO net arm. We could not calculate CIs as the standard errors were not given for the means.

- **West 2014** reported no reduction in the mean number of infected bites per household per month when IRS was added to ITNs (1.1, 95% CI 0.4 to 2.8 in the ITN-only arm and 1.3, 95% CI 0.4 to 4.4 in the IRS plus ITNs arm). This finding was inconsistent with the epidemiological outcomes, where the trial reported a large reduction in both malaria parasite prevalence and anaemia prevalence.

Two trials reported the effect on the sporozoite rate (Protopopoff 2018; West 2014). Both defined this outcome as the proportion of *An. gambiae s.l.* caught from light traps with sporozoites.

- **In both comparisons of Protopopoff 2018**, the sporozoite rate was lower when IRS was added. In the IRS plus standard ITNs arm the proportion was 0.4% versus 2.8% in the standard ITNs alone comparison. In the IRS plus pyrethroid-PBO net arm the proportion was 0% versus 0.7% in the pyrethroid-PBO net alone comparison. The trial did not report 95% CIs for these measurements or an overall effect estimate.

- **West 2014** reported a 28% reduction in the odds of a mosquito being infected with sporozoites in the intervention arm compared to the control arm, but the CI included no effect (OR 0.72, 95% CI 0.21 to 2.53).

Table 7 summarizes the characteristics and effects of all trials reporting the sporozoite rate included in this review.

**Adult mosquito density**

One trial measured adult mosquito density as a biting rate (Corbel 2012), and as the number of adult mosquitoes caught per trap per night in both trials conducted in Tanzania (Protopopoff 2018; West 2014). The differences in the reporting of these outcomes precluded a quantitative synthesis. In summary, all three trials reported a reduction in adult mosquito density when IRS was added.

- **Corbel 2012** reported a reduction of bites by 31% in the intervention arm compared to the control arm, but the CIs were wide and included no effect (rate ratio 0.69, 95% CI 0.38 to 1.25).

- **In the IRS plus standard ITNs versus standard ITNs alone comparison, Protopopoff 2018** reported a mean number of 2.37 vectors caught per night per household in the intervention arm and 2.83 vectors per night per household in the control arm. In the IRS plus pyrethroid-PBO nets the mean number was 1.85 versus 1.84 in the pyrethroid-PBO nets alone comparison. As with the above EIR outcome, the trial did not report 95% CIs for these measurements or an overall effect estimate.

- **West 2014** reported a 77% reduction of adult mosquitoes in the intervention arm compared to the control arm, but the CIs included no effect (rate ratio 0.23, 95% CI 0.04 to 1.32).

Table 8 summarizes the characteristics and effects of all trials reporting adult mosquito density included in this review.

**Anaemia prevalence**

Two trials assessed the effect on anaemia prevalence. One trial provided two comparisons to the analysis, one comparing standard ITNs plus IRS versus standard ITNs alone, and a second comparing pyrethroid-PBO nets plus IRS versus pyrethroid-PBO nets alone. Similarly to the previous outcomes, the introduction
of IRS with a standard ITN was associated with a reduction in the prevalence of anaemia compared to a standard ITN alone (RR 0.17, 95% CI 0.04 to 0.67), but the combination of IRS plus pyrethroid-PBO net was not favourable to a pyrethroid-PBO net alone (RR 1.18, 95% CI 0.09 to 15.08). Across the included studies, the pooled analysis showed that the prevalence of anaemia was lower when IRS was added to communities using ITNs (RR 0.46, 95% CI 0.18 to 1.20; 2 cRCTs, 2026 participants; Analysis 1.4; low-certainty evidence), and the meta-analysis showed moderate heterogeneity between trials (I² = 41%). As there are only two trials, a subgroup analysis by ITN usage was not considered to be useful.

Insecticide resistance
Corbel 2012 reported the allelic frequency of 1014F kdr, a genetic marker associated with resistance to pyrethroid insecticide in mosquitoes. There was no difference detected in the frequency of 1014F kdr in the IRS plus ITNs arm (80%, 95% CI 80% to 92%) compared to the ITN-only arm (86%, 95% CI 79% to 93%). The trial did not report the individual frequency in each intervention arm of G119S ace1, a genetic marker associated with resistance to carbamate insecticides. However, it commented that the allele was almost absent across the study area during the trial (less than 5%, 2123 participants).
Kafy 2017 reported that there was less phenotypic pyrethroid resistance in the IRS plus ITNs arm, with 68% mosquito mortality after exposure to deltamethrin (95% CI 60.0% to 76.0%) compared to 56.1% mortality in the ITN-only arm (95% CI 47.1% to 64.9%).

Comparison 2: adding IRS with pyrethroid-like insecticides to ITNs
See Summary of findings 2.

Malaria incidence
The two trials that reported the effect on malaria incidence did not detect an effect of IRS in communities that were using ITNs (rate ratio 1.07, 95% CI 0.80 to 1.43; 2 cRCTs, 15,717 child-years; Analysis 2.1; moderate-certainty evidence).

Malaria parasite prevalence
The three trials that reported the effect on malaria parasite prevalence did not detect an effect of IRS in communities that were using ITNs, with no heterogeneity between the studies (RR 1.11, 95% CI 0.86 to 1.44; 10,820 participants; Analysis 2.2; moderate-certainty evidence).

Entomological inoculation rate
One trial reported the effect on the estimated EIR (Pinder 2015). The authors defined the estimated EIR as the mean number of infected bites per person per transmission season. In the first year, the trial reported a difference in the estimated EIR of 2.44 (95% CI 0.69 to 6.39) without IRS and 1.08 (95% CI 0.16 to 4.02) when IRS was added, but the CIs overlapped. The pattern in the point estimates was the same in the second year, with an estimated EIR of 1.45 (95% CI 0.15 to 5.69) without IRS and 0.29 (95% CI 0.00 to 2.66) when IRS was added. While the point estimates were not consistent with the human data, the wide CIs make no inference possible. Table 6 summarizes the characteristics and effects of all trials reporting the EIR included in this review.

Sporozoite rate
One trial reported the effect on the sporozoite rate (Pinder 2015). The authors defined this as the proportion of An gambiae s.l. caught using light traps, with sporozoites. The actual number of infected mosquitoes detected was small (19 in both arms across the two years). In the first year of assessment, 0.19% (4/2131) of An gambiae s.l. were positive in the intervention arm, and 0.32% (9/2829) were positive in the control arm. The risk of a mosquito being infected with sporozoites was 41% lower in the intervention arm compared to the control arm, but the analysis was underpowered (RR 0.59, 95% CI 0.18 to 1.91). In the second year of assessment, 0.65% (5/773) of An gambiae s.l. were positive in the intervention arm and 0.09% (1/1131) in the control arm. The risk of a mosquito being infected with sporozoites was more than seven times higher in the intervention arm compared to the control arm, but again this was underpowered (RR 7.32, 95% CI 0.86 to 62.5). Table 7 summarizes the characteristics and effects of all trials reporting the sporozoite rate included in this review.

Adult mosquito density
One trial reported the effect on adult mosquito density (Pinder 2015). The authors defined this outcome as the number of An gambiae s.l. per trap per night. The trial used both light and exit traps. There were no clear differences between the arms, and the CIs were wide (2010 using light traps: MD -1.22, 95% CI -3.58 to 1.14; 2010 using exit traps: MD -0.13, 95% CI -0.54 to 0.28; 2011 using light traps: MD -0.69, 95% CI -2.15 to 0.77; and 2011 using exit traps: MD -0.40, 95% CI -1.05 to 0.25). Table 8 summarizes the characteristics and effects of all trials reporting adult mosquito density included in this review.

Anaemia prevalence
The one trial that reported the prevalence of anaemia did not detect an effect of IRS in communities that were using ITNs (RR 1.12, 95% CI 0.89 to 1.40; 4186 participants, 1 cRCT; Analysis 2.3; low-certainty evidence).
**Insecticide resistance**

No trials reported level of insecticide resistance in such a way that an effect size could be calculated. However, Kafy 2017 reported that in the first year of the trial there was no difference in mosquito deltamethrin mortality when IRS was added (65%, 95% CI 49% to 81%) compared to the control arm (60%, 95% CI 44% to 76%).
## Pyrethroid-like indoor residual spraying (IRS) + insecticide-treated nets (ITNs) versus ITNs alone for preventing malaria

**Patient or population:** people at risk of malaria  
**Setting:** sub-Saharan Africa (The Gambia, Sudan, Eritrea)  
**Intervention:** combination of IRS + ITNs - using an insecticide for IRS that has the same target site as the pyrethroids used in ITNs  
**Comparison:** ITNs alone

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Anticipated absolute effects* (95% CI)</th>
<th>Relative effect (95% CI)</th>
<th>Number of participants (studies)</th>
<th>Certainty of the evidence (GRADE)</th>
<th>Comments:</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Malaria incidence</strong></td>
<td></td>
<td>Rate ratio 1.07 (0.80 to 1.43)</td>
<td>15,717 child-years (2 comparisons, 2 cRCTs)</td>
<td>Moderate</td>
<td>Probably had little or no effect on malaria incidence compared to ITNs alone</td>
</tr>
<tr>
<td></td>
<td>Risk with ITNs alone</td>
<td>Risk with IRS + ITNs</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>215 cases per 1000 child-years</td>
<td>230 cases per 1000 child-years (172 to 307)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Malaria parasite prevalence</strong></td>
<td>Risk ratio 1.11 (0.86 to 1.44)</td>
<td>10,820 participants (4 comparisons, 3 cRCTs)</td>
<td>Moderate</td>
<td>Probably had little or no effect on malaria parasite prevalence compared to ITNs alone</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Risk with ITNs alone</td>
<td>Risk with IRS + ITNs</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>13.2 cases per 100</td>
<td>14.7 cases per 100 (11.4 to 19.0)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>EIR</strong></td>
<td>Mean EIR was lower with IRS and ITNs than ITNs alone</td>
<td>(2 comparisons, 1 cRCT)</td>
<td>Very low</td>
<td>We do not know if there was an effect on the EIR compared to ITNs alone.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Anaemia prevalence</strong></td>
<td>Risk ratio 1.12 (0.89 to 1.40)</td>
<td>4186 participants (2 comparisons, 1 cRCT)</td>
<td>Low</td>
<td>May have had little or no effect on anaemia prevalence compared to ITNs alone</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Risk with ITNs alone</td>
<td>Risk with IRS + ITNs</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>42.6 cases per 100</td>
<td>47.7 cases per 100 (37.9 to 59.6)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
The risk in the intervention arm (and its 95% CI) is based on the assumed risk in the comparison arm and the relative effect of the intervention (and its 95% CI). The assumed risk of the comparison arm is calculated from the total number of events/total number of participants in the control arms of the trials contributing to the meta-analysis. CI: confidence interval; cRCT: cluster randomized controlled trial; IRS: indoor residual spraying; ITN: insecticide-treated net; RR: risk ratio.

GRADE Working Group grades of evidence

High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.

Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.

Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.

Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.

\( ^a \) Downgraded one level for serious imprecision: the CIs were wide and included both an increase and decrease in the outcome.

\( ^b \) Downgraded one level for serious indirectness: the evidence was provided from one trial only and it was not certain that the reported effect would be seen in other malaria transmission settings.

\( ^c \) Downgraded two levels for very serious imprecision: the CIs for the mean EIR in the intervention arms were very wide, including values that would represent both large increases and reductions from the mean EIR in the control arms.

\( ^d \) The EIR was low in the control arm, ranging from 1.45 to 2.4 infectious bites per person per transmission season. While the point estimate of the EIR in the intervention arm was lower than the control, the CIs overlapped. The absolute difference in EIR was operationally unimportant.
**DISCUSSION**

**Summary of main results**

See Summary of findings for the main comparison and Summary of findings 2.

Adding IRS using a non-pyrethroid-like insecticide to ITNs gave mixed results and we could not explain why there were such differences between the trials. There was some indication of an added effect on malaria and anaemia prevalence in some of the trials.

Adding IRS using a pyrethroid-like insecticide to ITNs did not provide any improvement in malaria outcomes in the two trials to date.

For both comparisons included in this review, entomological outcomes were reported inconsistently, and qualitative comparisons with the human malaria outcomes showed poor correlation in relation to the presence or absence of an effect.

**Certainty of the evidence**

Details of the downgrading for GRADE are contained in the 'Summary of findings' tables. There was a large amount of qualitative heterogeneity, with some studies reporting large effects, and some studies reporting little or no effect in the primary outcomes. This decreased the certainty of the evidence and raised doubts about the generalizability to other settings.

**Overall completeness and applicability of evidence**

Given the wide geographical variety of malaria endemicities, transmission patterns, and insecticide resistance, we need to be cautious with inferences to policy from the limited number of trials conducted to date. The review included six trials, which were divided into two main comparisons. With so few trials, showing variable results, it was difficult to confidently draw conclusions about the impact of adding IRS to ITNs. Applicability of vector control interventions in different settings is always a concern. This is because only a few trials are conducted in very specific contexts. The ecology, behaviour, and insecticide-resistance profiles of *Anopheles* mosquitoes can vary massively between and within species. The included studies in this review are all conducted in Sub-Saharan Africa, between 2008 and 2016, with primary vectors all belonging to the *An gambiae s.l.* species complex (Table 4). The effect of combining IRS with ITNs in the trials reported here will not necessarily apply to other target species in other settings, particularly those which are more exophilic and exophagic (Okumu 2011).

The rationale for adding IRS to ITNs can be framed in three contexts, and the applicability of the evidence to each of these is discussed below.

First, where the maximum reduction of malaria that is feasibly possible has already been achieved with one intervention, an incremental impact may be expected by adding a second intervention that also targets endophilic and endophagic mosquitoes (Okumu 2011). Though current WHO policy does not recommend the addition of IRS where ITN compliance is low, instead favouring the target of universal coverage of one core intervention, suggestions have been made that rolling out IRS in an area with low ITN compliance would compensate for the poor usage of ITNs (WHO 2014a). Our review presented findings from two trials conducted in areas of low ITN compliance, with one in Benin and the other in Tanzania, but the two trials had conflicting results (Corbel 2012; West 2014).

A second rationale is that the addition of IRS may be useful in an area where high pyrethroid resistance is causing ITNs to fail. When the trials included in this review were conducted, only pyrethroids were approved for use on ITNs, whereas four classes of insecticides (including pyrethroids) could be used for IRS (WHO 2014b; WHO 2014c; WHO 2015a). By adding a non-pyrethroid-like IRS to a pyrethroid ITN, one would expect the reduction in efficacy due to pyrethroid resistance to be compensated for (WHO 2012). Our review attempted to explore this by presenting separate analyses dependent on the target site of the insecticides used for IRS. The rationale behind this was that if pyrethroid resistance is causing ITNs to fail, introducing a pyrethroid-like IRS will be unlikely to have a benefit. The included trials that used pyrethroid-like insecticides followed this rationale, showing no effect on epidemiological outcomes. In contrast, introducing an non-pyrethroid-like IRS should improve malaria disease outcomes. The findings of Kafy 2017 in particular support this conclusion, reporting reductions in malaria prevalence and incidence only in the second and third years of the trial when the insecticide used for IRS was changed to one with a non-pyrethroid target site. Several trials using non-pyrethroid-like insecticides showed a clear benefit of IRS with large reductions in prevalence, but one study had higher malaria prevalence in the intervention arm (Corbel 2012). To further investigate this unexpected result, we re-examined the manuscript of Corbel 2012, which is reported in meticulous detail. Though the trial was considered at high risk of attrition bias, this was due to the number of theoretical child days lost to follow up being higher in the intervention arm than in the control arm. This potential bias would therefore be unlikely to overestimate the malaria prevalence in the intervention arm. The trial was conducted in an area of moderate allelic frequency of 1014F kdr, associated with resistance to pyrethroids. There was high coverage of IRS, and though ITN use during the trial was low, this was not lower than another trial in the subgroup that reported a significant effect (West 2014). This suggests their findings of no clear evidence of benefit are valid, and not related to problems implementing the intervention. As a result, there remains considerable unexplained heterogeneity between trials for this comparison. More research will be needed to understand this heterogeneity in order to predict
when and where the combination of IRS and ITNs will have an impact.

The findings of Protopopoff 2018 may help to indirectly assess the relative importance of the above two concepts. In the trial, the combination of IRS with pyrethroid-PBO nets provided no additional benefit compared to pyrethroid-PBO nets alone, suggesting that the majority of the benefit seen when IRS was combined with a standard ITN was due to the addition of an insecticide that is effective against pyrethroid-resistant mosquitoes, rather than due to the incremental impact of adding a second core intervention. Third, one potential justification for combining a non-pyrethroid-like IRS with ITNs is to restore susceptibility to pyrethroids in the vector, or to prevent the emergence of resistance in the first place. By this rationale, waiting to implement the combination of IRS with ITNs until incremental impact is demonstrated over ITNs alone may mean doing so far too late (Killeen 2018). While many studies characterized insecticide resistance (either phenotypically, genotypically, or both) at the start of the follow-up period, only two trials continued to monitor the changes in insecticide resistance postintervention rollout. The reporting of such outcomes was heterogeneous, and we were unable to adequately explore the effect that mass rollout of both core interventions would have on insecticide resistance. While standardized methods of measuring and reporting insecticide resistance would help to compare these results between studies, it remains a matter of conjecture whether a considerable change in resistance would be detected within the period of a typical RCT.

Potential biases in the review process

We did not anticipate in our protocol separating the analyses by whether the insecticide used for IRS had a pyrethroid-like or non-pyrethroid-like target site (Choi 2017). However, because policy makers and specialists in the field considered this to be critical to decision making - to the extent that it would be unusual for anyone to recommend pyrethroid-like insecticides for use in IRS - we separated the analysis to be policy-relevant.

Agreements and disagreements with other studies or reviews

There has been no other systematic review conducted on this topic. A narrative review published by the WHO included the studies by Corbel 2012; Pinder 2015; and West 2014 (WHO 2014d). The review suggested that West 2014 differed from the other studies, showing a reduction in malaria epidemiological outcomes favouring the intervention because the study area had low ITN usage. However, our review includes new trials that show a reduction in epidemiological outcomes even in areas with high ITN usage. Whether or not the IRS was conducted using a pyrethroid-like appears to be a better predictor for success or failure of the intervention, although there remains some heterogeneity when a non-pyrethroid-like insecticide is used. Where we have conducted subgroup analysis to explore this heterogeneity, ITN usage was not shown to be an effect modifier.

Authors’ conclusions

Implications for practice

Four trials tested adding IRS using a non-pyrethroid-like insecticide to ITNs, and gave mixed results. Three trials tested adding indoor residual spraying (IRS) using a pyrethroid-like insecticide to insecticide-treated nets (ITNs), and did not detect an improvement in malaria outcomes. Thus, given the current evidence assessed in this review, adding IRS in either set of circumstances is difficult to justify on the basis that it will improve malaria control. The evidence from these trials was also insufficient to evaluate whether adding IRS in communities using ITNs would be an effective strategy to prevent pyrethroid resistance emerging.

Implications for research

In some trials assessing the combination of non-pyrethroid-like IRS with ITNs, the effects were substantial, but this effect was absent in one trial. This creates uncertainty and needs further studies to unravel these conflicting results. Researchers and policy makers may wish to consider programme implementation using quasi-experimental methods, such as stepped wedge designs. Improved and standardized methods for measuring and reporting pyrethroid resistance will help comparisons between studies.

Acknowledgements

The Academic Editor is Dr Jimee Hwang, and the Sign-off Editor is Dr Hellen Gelband.

We are grateful to Vittoria Lutje, Information Specialist with the Cochrane Infectious Diseases Group (CIDG), for help with the literature search strategy.

Leslie Choi, Joseph Pryce, and Paul Garner are supported by the Research, Evidence and Development Initiative (READ-It). READ-It and the CIDG editorial base are funded by UK aid from the UK government for the benefit of low- and middle-income countries (project number 300342-104). The views expressed do not necessarily reflect the UK government’s official policies.

Leslie Choi is supported by PIIVeC, the Partnership for Increasing the Impact of Vector Control. PIIVeC is funded by the Medical Research Council of the UK (grant number MR/P027873/1) through the Global Challenges Research Fund.
This work was partly supported through a grant from the Global Malaria Programme, WHO (WHO Global Malaria Programme Agreement for Performance of Work (APW) Grant 2017 (number 709319)). The views expressed in this review have not been influenced by, or necessarily reflect, WHO policy.

REFERENCES

References to studies included in this review

Corbel 2012 (published data only)

Kafy 2017 (published data only)

Keating 2011 (published data only)

Pinder 2015 (published data only)

Protopopoff 2018 (published data only)

West 2014 (published data only)

References to studies excluded from this review

Abeku 2014 (published data only)

Bekele 2012 (published data only)

Diallo 2015 (published data only)

Fullman 2013 (published data only)

Gari 2016 (published data only)
Indoor residual spraying for preventing malaria in communities using insecticide-treated nets (Review)

Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.

Gimnig 2016 [published data only]

Hamel 2011 [published data only]

Katureebe 2016 [published data only]

Kitau 2015 [published data only]

Protopopoff 2007a [published data only]

Protopopoff 2007b [published data only]

Protopopoff 2015a [published data only]

Protopopoff 2015b [published data only]

Pinder 2011 [published data only]

Pinder 2012 [published data only]

Protopopoff 2007a [published data only]


References to studies awaiting assessment

Chaccour 2018 {published data only}

Deressa 2016 {published data only}  


Hamainza 2016 {published data only}

Additional references

Balshem 2011

Bhatt 2015

Deeks 2011

Gleave 2018

Goodman 2001

Guyatt 2011

Harbord 2006

Higgins 2011a

Higgins 2011b

Killeen 2006

Killeen 2018

Kitau 2012

Kleinschmidt 2009
Ojuka 2015


Okumu 2011


Pluess 2010


Pryce 2018

Pryce J, Richardson M, Lengeler C. Insecticide-treated nets for preventing malaria. *Cochrane Database of Systematic Reviews* 2018, Issue 11. DOI: 10.1002/14651858.CD000363.pub3

Review Manager 2014 [Computer program]


Shililu 2004


WHO 2011


WHO 2012


WHO 2014a


WHO 2014b


WHO 2014c


WHO 2014d


WHO 2015a


WHO 2015b


WHO 2015c


WHO 2017a


WHO 2017b


Yakob 2011


Zaim 2000


References to other published versions of this review

Choi 2017

Choi I, Pryce J, Garner P. The combination of indoor residual spraying with insecticide-treated nets versus
insecticide-treated nets alone for preventing malaria.

DOI: 10.1002/14651858.CD012688

* Indicates the major publication for the study
### Characteristics of included studies  
*ordered by study ID*

#### Corbel 2012

| Methods | Study design: cRCT with 4 intervention arms  
|         |   • LLIN targeted to pregnant women and children aged < 6 years (TLLIN)  
|         |   • TLLIN + full coverage of carbamate IRS (TLLIN + IRS)  
|         |   • ULLIN  
|         |   • ULLIN + CTPS  
|         | Unit of allocation: clusters (villages)  
|         | Number of units: 28 villages randomized into 4 arms equally  
|         | Outcome assessment/surveillance type: 60 children randomly selected from each village to participate in the study  
|         |   • Active case detection for malaria episodes was done on the cohort of children during 12 periods of 6 consecutive days at 6-weekly intervals. Thick blood films were taken from every sick child.  
|         |   • Cross-sectional surveys were done at each period of clinical monitoring on every asymptomatic child who showed an axillary temperature < 37.5 °C. A thick film sample was taken on the fourth day to ensure that asymptomatic children were not sick in preceding days.  
|         |   • From 14 January to 24 December 2009, mosquitoes were collected through 8 surveys of 2 consecutive days every 6 weeks. This collection occurred 2 weeks before medical surveys. Sporozoite rate was detected using ELISA of heads and thoraces for *P. falciparum* CSP.  
|         | Length of follow-up: 18 months (23 June 2008 to 24 December 2009)  
|         | Adjustment for clustering: yes  
|         |  
| Participants | Number of participants: 3018 (429) TLLIN, 1996 (420) ULLIN, 2251 (415) ULLIN + CTPS, 2660 (413) TLLIN + IRS  
|            | Population characteristics:  
|            |   • TLLIN arm coverage to pregnant women and children aged < 6 years  
|            |   • Moderate level of pyrethroid resistance in malaria vectors (> 40% kdr allelic frequency)  
|            |   • Population size of 250-500 inhabitants with non-isolated habitations  
|            |   • Absence of a local health centre  
|            |   • Inclusion criteria for children were age (0-71 months) and their effective domiciliation in these village  
|            | Withdrawal and loss to follow-up: in every arm, about 20% of the recordings were not taken into account because of loss to follow-up (17%), death of children (1.5%), and refusal (1.5%)  
| Interventions | Relevant comparison for this review: TLLIN versus TLLIN + IRS  
|              | IRS:  
|              |   Active ingredient and dosage: bendiocarb 400 mg/m²  
|              |   Formulation: wettable powder  
|              |   Frequency of spraying: every 8 months  
|              |   Coverage: aimed for 80% coverage as per WHO recommendations  
|              |   Buffer size between clusters: minimum 2 km between villages  

---

**Indoor residual spraying for preventing malaria in communities using insecticide-treated nets (Review)**  
Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.
Corbel 2012  (Continued)

**ITN:**
Active ingredient and dosage: deltamethrin 55 mg (PermaNet 2.0)
Coverage: for TLLIN coverage, 1 LLIN was provided per sleeping unit of children < 6 years or pregnant women, or both, whereas 1 net was given to every sleeping unit for ULLIN coverage. Overall, this corresponded to a mean of 1 LLIN every 4 people for TLLIN and 1 net for every 2 people for ULLIN (census showed that the mean number of people per house was 4). Coverage was defined as the total number of hung nets relative to the total number of sleeping units. Mean coverage was low: 38% in the control arm and 45% in the intervention arm.
Compliance: defined as proportion of children aged < 6 years sleeping under the net the night preceding the visit. Mean compliance was low: 58% in the control arm and 45% in the intervention arm.

**Control:** ITN only as above
**Cointerventions:** none reported

**Outcomes**
Incidence density rates of *P falciparum* clinical malaria in children aged < 6 years (defined as malaria symptoms + a parasite density > 2000 parasites/µL)
Prevalence of asymptomatic infections in children aged < 6 years
Parasite density of asymptomatic infections in children aged < 6 years
EIR (as defined by the number of infected bites per person per year)
Prevalence of pyrethroid-resistant 1014F kdr allele and carbamate-resistant G119S ace1 allele in malaria vectors
Geometric mean of *P falciparum* parasites/µL

**Location profile**
**Study location:** Ouidah-Kpomasse-Tori Bossito health district, southern Benin
**Malaria endemicity:** mesoendemic
**EIR:** control arm reported an annual mean of 9.4 infected bites/person/year (range 5.1-17.1)
**Population proximity/density:** density/km²
TLLIN: 449
ULLIN: 462
ULLIN + CTPS: 577
TLLIN + IRS: 579
**Plasmodium spp:** *P falciparum*

**Vector profile**
**Primary (and secondary) vector species:** *An. gambiae* s.l. and *An. funestus* s.l.
**Vector behaviour (nature, stability, adult habitat, peak biting times, exophilic/endophilic, exophagic/endophagic, anthropophilic/zoophilic):** not measured
**Phenotypic resistance profile:** not measured
**Genotypic resistance profile:** moderate kdr allelic frequency and virtually no ace1 allelic frequency
**Method of mosquito collection:** adult female mosquitoes were caught using human landing catches technique both indoors and outdoors at 4 sites per village from 10 p.m. to 6 a.m. and for 2 consecutive nights per survey (that is, 16 person-nights per village per survey). Independent staff regularly checked quality of the mosquito collections on a randomly selected sample representing 12% of the total night-collection

**Notes**
### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Quote: “In each village, we randomly selected 60 children aged &lt; 6 years from the census list of the inhabitants to participate using computer-generated random numbers. The allocation sequence and randomization of the blocks and children were prepared by the study statistician at IRD-CREC.”</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Low risk</td>
<td>Children and study investigators were not blinded to treatment allocation but allocation sequence and randomization of the blocks and children were prepared by the study statistician at IRD-CREC</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias)</td>
<td>Low risk</td>
<td>Participants and personnel were not blinded to intervention.</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias)</td>
<td>Low risk</td>
<td>Participants and personnel were not blinded to intervention. Low risk of bias for prevalence as all cohort members had their blood taken</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>Unclear risk</td>
<td>Participants and personnel were not blinded to intervention. Unclear risk of bias for incidence due to self-reporting of sickness before confirmation by microscopy, an objective assessment</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>Low risk</td>
<td>Participants and personnel were not blinded to intervention. Low risk of bias for prevalence as all cohort members had their blood taken</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>High risk</td>
<td>Loss to follow-up performed but over 10% difference in children-days between the 2 arms: 5224 theoretical children-days missing in control arm, 6688 children-days missing in intervention arm</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Low risk</td>
<td>All children-days were analyzed. The study protocol reported 1 each outcome as stated in the clinical trials register (note: retrospectively registered)</td>
</tr>
</tbody>
</table>
### Corbel 2012  (Continued)

<table>
<thead>
<tr>
<th>Bias</th>
<th>Risk level</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Recruitment bias</td>
<td>Low risk</td>
<td>Cohort of children were randomly selected.</td>
</tr>
<tr>
<td>Baseline imbalance</td>
<td>Low risk</td>
<td>Baseline data were displayed. No significant differences at baseline between intervention arms for incidence ($P = 0.78$). The prevalence was significantly higher in the TTLIN + IRS arm ($P = 0.01$). Entomological outcomes were not provided at baseline</td>
</tr>
<tr>
<td>Loss of clusters</td>
<td>Low risk</td>
<td>No clusters were lost.</td>
</tr>
<tr>
<td>Incorrect analysis</td>
<td>Low risk</td>
<td>Adjustment for clustering was done.</td>
</tr>
<tr>
<td>Comparability with RCTs randomizing participants</td>
<td>Low risk</td>
<td>Because the intervention is expected to have community level impact as well as individual impact, cRCTs are the most appropriate study design to capture this</td>
</tr>
<tr>
<td>Other bias</td>
<td>Low risk</td>
<td>No other biases.</td>
</tr>
</tbody>
</table>

### Kafy 2017

#### Methods

**Study design:** cRCT with 2 intervention arms  
**Unit of allocation:** clusters (villages)  
**Number of units:** 26 villages randomized into 2 arms equally. Each cluster consisting of ≥500 households  
**Outcome assessment/surveillance type:** 60 children randomly selected from each village to participate in the study  
- Active case detection for malaria episodes was done on the cohort of children aged 0.5-10 years weekly during the peak of the malaria season (September to November) and fortnightly during the remainder of the year, for a total of 30 annual visits. during 12 periods of 6 consecutive days at 6-weekly intervals. Malaria was confirmed by RDT (SD BIOLINE-Malaria Ag Pf/Pv; Standard Diagnostics, Inc.), or microscopy, or both.  
- Prevalence of infection was measured once each year, during September to October. Cohort of children were tested for *P falciparum* infection using RDTs (SD BIOLINE-Malaria Ag Pf/Pv; Standard Diagnostics, Inc.) irrespective of symptoms.  
**Length of follow-up:** 1 June 2012 to 31 May 2015  
**Adjustment for clustering:** yes

#### Participants

**Number of participants:** total population in study area in 2011 was 139,566. Over the 3-year study period, 7529 children were recruited who were followed up cumulatively for 17,284 person-years  
**Population characteristics:** a baseline household census estimated that the area comprised approximately 119,000 households in 197 villages with 600,000 inhabitants who were predominantly dependent on rain-fed agriculture. Mean age of cohort children were similar across all study arms (about 5-6 years old)  
**Withdrawal and loss to follow-up:** not reported
### Interventions

**Comparison: IRS + ITN versus ITN alone**

**IRS:**
- Active ingredient, dosage, and formulation: deltamethrin 25 mg/m² in 2012 (formulation not reported, Chema Industries), bendiocarb 200 mg/m² in 2013 and 2014 (Ficam 80%, wettable powder, Bayer)
- Frequency of spraying: IRS was conducted in August and late December of each year
- Coverage: 99% in 2012, 82% in 2013, and 83% in 2014
- Buffer size between clusters: minimum 3 km between the edges of adjoining clusters

**ITN:**
- Active ingredient and dosage: deltamethrin 55 mg (PermaNet 2.0)
- Coverage: an annual intervention assessment survey showed that household net ownership was 99.6% in 2012, 82.1% in 2013, and 98.6% in 2014
- Compliance: defined as the proportion of affirmative responses to the question “Did this child sleep under an LLIN last night?” In 2012, this was 79% in both arms. In 2013, it was 74% in the LLIN-only arm and 75% in the LLIN + IRS arm. In 2014, it was 82% in both study arms.
- **Control:** ITN only as above
- **Cointerventions:** none reported

### Outcomes

- Incidence of malaria in children aged 0.5-10 years
- Prevalence of malaria infection in children aged 0.5-10 years
- Deltamethrin susceptibility using WHO discriminating dose tests
- Prevalence of pyrethroid-resistant 1014F kdr allele
- Cost and cost-effectiveness

### Location profile

**Study location:** Galabat, south-eastern Sudan, located around 80 km from Gedarif town and borders Ethiopia
**Malaria endemicity:** highly seasonal
**EIR:** not reported
**Population proximity/density:** not reported
**Plasmodium spp:** P. falciparum accounts for 95% of the malaria burden

### Vector profile

**Primary (and secondary) vector species:** *An. arabiensis*
**Vector behaviour (nature, stability, adult habitat, peak biting times, exophilic/endophilic, exophagic/endophagic, anthropophilic/zoophilic):** not reported
**Phenotypic resistance profile:** mean percentage mortality in the LLIN arm (65.0%, 95% CI 44.6% to 85.3%) was not significantly different from that of the LLIN + IRS arm (60%, 95% CI 38.2% to 82.2%) during 2012 (t = 0.425; degrees of freedom 9; P = 0.68)
**Genotypic resistance profile:** Vgsc-1014F allelic frequency was around 60% in mosquitoes sampled from both study arms in 2012

**Method of mosquito collection:** *Anopheles* larvae and pupae were collected annually during the rainy season. Adults were collected using pyrethrum spray catches. 24 *An. arabiensis* females per cluster were selected at random for Vgsc-1014F genotyping to estimate a cluster-specific resistance marker frequency

### Notes

**Risk of bias**
<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Clusters were randomly allocated using a restricted randomization computerized</td>
</tr>
<tr>
<td></td>
<td></td>
<td>procedure. Balance criteria were prevalence of <em>P. falciparum</em> infection, ITN use,</td>
</tr>
<tr>
<td></td>
<td></td>
<td><em>kdr</em> frequency in <em>An. arabiensis</em> and cluster population size. Out of 200,000</td>
</tr>
<tr>
<td></td>
<td></td>
<td>random allocations, 8000 yielded balance between study arms on these criteria, from</td>
</tr>
<tr>
<td></td>
<td></td>
<td>which 1 sequence was randomly selected</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Low risk</td>
<td>The 26 clusters in Gedarif, Sudan were randomized to receive LLIN + IRS or LLINs</td>
</tr>
<tr>
<td></td>
<td></td>
<td>alone, using restricted randomization to ensure balance between study arms</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Balance criteria were: prevalence of <em>P. falciparum</em> infection and ITN use as</td>
</tr>
<tr>
<td></td>
<td></td>
<td>determined in a baseline survey, <em>kdr</em> frequency in <em>An. arabiensis</em> from a survey</td>
</tr>
<tr>
<td></td>
<td></td>
<td>of mosquito collections carried out in each cluster, and cluster population size.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Out of 200,000 random allocations of the 26 clusters, 8000 yielded balance between</td>
</tr>
<tr>
<td></td>
<td></td>
<td>study arms on these criteria. Of these, 1 allocation was randomly chosen, after</td>
</tr>
<tr>
<td></td>
<td></td>
<td>verifying that the imposed restriction did not introduce undue dependence between</td>
</tr>
<tr>
<td></td>
<td></td>
<td>clusters</td>
</tr>
<tr>
<td>Blinding of participants and personnel</td>
<td>Low risk</td>
<td>Participants and personnel were not blinded to intervention. Low risk of bias for</td>
</tr>
<tr>
<td>(performance bias)</td>
<td></td>
<td>both incidence and prevalence. RDTs and microscopy were used to confirm malaria</td>
</tr>
<tr>
<td>Incidence of malaria</td>
<td></td>
<td>infection</td>
</tr>
<tr>
<td>Blinding of participants and personnel</td>
<td>Low risk</td>
<td>Participants and personnel were not blinded to intervention. Low risk of bias for</td>
</tr>
<tr>
<td>(performance bias)</td>
<td></td>
<td>both incidence and prevalence. RDTs and microscopy were used to confirm malaria</td>
</tr>
<tr>
<td>Prevalence of malaria</td>
<td></td>
<td>infection</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>Low risk</td>
<td>Participants and personnel were not blinded to intervention. Low risk of bias for</td>
</tr>
<tr>
<td>Incidence of malaria</td>
<td></td>
<td>both incidence and prevalence. RDTs and microscopy were used to confirm malaria</td>
</tr>
<tr>
<td></td>
<td></td>
<td>infection</td>
</tr>
</tbody>
</table>
### Kafy 2017  (Continued)

| Blinding of outcome assessment (detection bias) | Low risk | Participants and personnel were not blinded to intervention. Low risk of bias for both incidence and prevalence. RDTs and microscopy were used to confirm malaria infection |
| Prevalence of malaria | | |

| Incomplete outcome data (attrition bias) | Unclear risk | No report of withdrawals. |
| All outcomes | | |

| Selective reporting (reporting bias) | Low risk | All children-days were analyzed. The study protocol reports 1 each outcome as stated in the clinical trials register (note: retrospectively registered) |

| Recruitment bias | Low risk | Cohort of children were randomly selected |
| | | |

| Baseline imbalance | Low risk | Although baseline information was not available, key effect modifiers such as age and LLIN usage were measured during the study and there were no significant differences |
| | | |

| Loss of clusters | Low risk | No clusters were lost. |
| | | |

| Incorrect analysis | Low risk | Adjustment for clustering was done. |

| Comparability with RCTs randomizing participants | Low risk | Because the intervention is expected to have community level impact as well as individual impact, cRCTs are the most appropriate study design to capture this |
| | | |

| Other bias | Low risk | No other biases. |

### Keating 2011

**Methods**

- **Study design:** cRCT with 2 intervention arms
- **Unit of allocation:** clusters (villages)
- **Number of units:** 58 randomized villages in each arm
- **Outcome assessment/surveillance type:** 15 houses within each village were randomly selected to serve as ultimate sampling units, giving 870 houses in each arm of the study. Household residents were given a questionnaire and took a RDT (Carestart) for malaria infection. Positive tests were confirmed by blood smear microscopy
- **Length of follow-up:** 3-4 months post spraying (6-15 October 2009)
- **Adjustment for clustering:** yes

**Participants**

- **Number of participants:** 7273 resided in participating houses. In the paper, 5508 total from Table 2 but 5502 stated in results
- **Population characteristics:** the distribution of participants living in houses located
in treatment and control villages was similar on sex, age, employment status of the respondent, and education level

**Withdrawal and loss to follow-up:** test refusal rates differed between treatment (8.5%) and control (12.7%) arms ($P < 0.05$)

### Interventions

**Comparison:** IRS + ITN versus ITN alone

**IRS:**
- Active ingredient and dosage: DDT 1-2 g/m²
- Formulation: wettable powder
- Frequency of spraying: once, June-July 2009
- Coverage: minimum 80% target (84.8% of households sampled sprayed within 12 months)
- Buffer size between clusters: > 5 km between intervention and control villages. In 2 instances whereby a treatment village was too close (< 5 km) to a control village, the closest village > 5 km was selected into the control arm

**ITN:** any ITN that was treated at least once in last 11 months, or was an LLIN
- Coverage: measured as people living in household owning $\geq$ 1 ITN: 75.8% (range 74.2% to 77.4%)
- Compliance: measured as individuals using ITN in the previous night: 50.7% (range 48.6% to 52.8%)

**Control:** ITN only as above
- Coverage: measured as people living in household owning $\geq$ 1 ITN: 72.0% (range 70.2% to 73.7%)
- Compliance: measured as people using ITN in the previous night: 46.2% (range 43.9% to 48.6%)

**Cointerventions:** larval habitat management and continued case management

### Outcomes

Malaria prevalence: parasite infection and febrile illness data from all household residents > 1 month old requiring a positive RDT (Carestart) and a positive thick blood film

### Location profile

**Study location:** Gash Barka, West lowlands of Eritrea, mostly rural and agricultural.
- Altitudes were 1500-3000 m above sea level. 30% of the country’s population lived here.
- Approximately 200 mm per year precipitation. Temperatures were extremely hot and dry climatic conditions with seasonal precipitation, concentrated in the summer months

**Malaria endemicity:** season with peak transmission occurring September-November.
- Smaller malaria season March-April

**EIR:** study references an estimated annual range of 0-70.6 ($Shililu$ 2004).

**Population proximity/density:** not reported

**Plasmodium spp:** $P$.falciparum with rare reports of $P$.vivax

### Vector profile

**Primary (and secondary) vector species:** An. arabiensis and An. gambiae s.s.

**Vector behaviour (nature, stability, adult habitat, peak biting times, exophilic/endophilic, exophagic/endophagic, anthropophilic/zoophilic):** not reported

**Phenotypic resistance profile:** not reported

**Genotypic resistance profile:** not reported

**Method of mosquito collection:** no entomological data collected

### Notes

36Indoor residual spraying for preventing malaria in communities using insecticide-treated nets (Review)

Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.
### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
</table>
| Random sequence generation (selection bias) | Unclear risk       | Quote: “Fifty-eight (58) villages within Gash Barka were randomly…”  
Comment: however randomization procedure was not described. |
| Allocation concealment (selection bias)   | Unclear risk       | Not stated.            |
| Blinding of participants and personnel (performance bias)  
Incidence of malaria | Low risk           | Outcome not reported.  |
| Blinding of participants and personnel (performance bias)  
Prevalence of malaria | Low risk           | Participants and personnel were not blinded to the intervention status; however, the outcome would not be affected by this knowledge |
| Blinding of outcome assessment (detection bias)  
Incidence of malaria | Low risk           | Outcome not reported.  |
| Blinding of outcome assessment (detection bias)  
Prevalence of malaria | Low risk           | Outcome assessors were not blinded to the intervention status; however, the outcome was measured using an objective tool (Carestart RDT) and would not be affected by this knowledge |
| Incomplete outcome data (attrition bias)  
All outcomes | Low risk           | Only one time point used, inapplicable |
| Selective reporting (reporting bias)       | Low risk           | The study only intended to report the relationship between IRS and parasite prevalence and this outcome was provided. Numbers appeared correct, assumed typographical error in table 2, should read 5502 |
| Recruitment bias                          | Low risk           | Households for survey were randomly selected. |
| Baseline imbalance                        | Unclear risk       | Baseline data were not displayed but due to randomization this should be accounted for |
| Loss of clusters                          | Low risk           | No mention of lost clusters. |
| Incorrect analysis                        | Low risk           | Adjustment for clustering was done. |
### Keating 2011 (Continued)

<table>
<thead>
<tr>
<th>Comparability with RCTs randomizing participants</th>
<th>Low risk</th>
</tr>
</thead>
<tbody>
<tr>
<td>Because the intervention is expected to have community level impact as well as individual impact, cRCTs are the most appropriate study design to capture this</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Other bias</th>
<th>Low risk</th>
</tr>
</thead>
<tbody>
<tr>
<td>No other biases.</td>
<td></td>
</tr>
</tbody>
</table>

### Pinder 2015

#### Study design:
Arm 1: IRS + LLIN
- **Active ingredient and dosage:** DDT target dose 2 g/m² (2010 mean: 1.69 g/m², 2011: 3.27 g/m²)
- **Formulation:** 75% wettable powder
- **Frequency of spraying:** once per transmission season (15-28 July 2010, and 20 July to 9 August 2011)
- **Coverage:** per cluster in 2010 (%): 86 (range 82.84-90.16); per cluster in 2011 (%): 83 (range 79.27-86.28)
- **Buffer size between clusters:** > 2 km

Arm 2: ITN (Olyset Net)
- **Active ingredient and dosage:** permethrin 2% w/w
- **Coverage:** nets were provided to cover all sleeping spaces as determined by a baseline survey. 59% coverage in June 2010. 89% coverage in January 2011. 93% in January 2012
- **Compliance:** not reported

#### Methods

- **Study design:** cRCT with 2 intervention arms
- **Unit of allocation:** clusters of villages, each cluster consisted of 1-3 neighbouring villages (97 villages in total)
- **Number of units:** 35 randomized clusters in each arm. A subset of 16 clusters per arm was used for entomological assessment
- **Outcome assessment/surveillance type:**
  - Children in the study villages aged 6 months to 14 years were sampled according to cluster size and enrolled into a study cohort
  - Incidence rates monitored through passive case detection at local health facilities
  - Prevalence and parasite rates were measured at the end of each transmission season
  - Mosquito density was assessed using light traps and exit traps in 6 sentinel sites in each of 32 clusters, 1 night per month
- **Length of follow-up:** 2 years (2010-2011), 2 transmission seasons (June-December 2010 and 2011)
- **Adjustment for clustering:** cluster adjusted measures were presented for some outcomes.

#### Participants

- **Number of participants:** control: 3949 enrolled children, intervention: 3896
- **Population characteristics:** cohort of children aged < 14 years. Ethnic origin varied with more Mandinka and lower Fula people in the LLIN arm than in the IRS + LLIN arm
- **Withdrawal and loss to follow-up:** separate analysis was done per survey, each time a survey was done, cohorts would be replenished
Control: ITN only as above
Compliance: not reported
Cointerventions: none reported

Outcomes

Primary:
Incidence of clinical malaria assessed by passive case detection
Number of *An. gambiae* s.l. collected per light trap per night

Secondary:
Haemoglobin concentration
Proportion of children with moderate anaemia (< 80 g/L) and severe anaemia (< 50 g/L)
Presence of malaria parasites
Parasite density
Proportion of children with high parasitaemia (> 5000 parasites/µL)
Prevalence of children with enlarged spleens measured at the end of the transmission season each year
Sporozoite rate estimates in trapped mosquitoes
Estimated EIR (mean number of infective mosquito bites per person per season)

Location profile

Study location: Upper River Region of The Gambia, > 110 children aged 6 months to 14 years on 1 June 2010
Malaria endemicity: moderate seasonal malaria transmission
EIR: estimated seasonal mean from the control arm of the study measured 2.44 (range 0.69-6.39) in the first year and 0.29 (0.003-2.66) in the second year
Population proximity/density: not reported
*Plasmodium* spp: *P. falciparum*

Vector profile

Primary (and secondary) vector species: *An. gambiae* s.l.
Vector behaviour (nature, stability, adult habitat, peak biting times, exophilic/endophilic, exophagic/endophagic, anthropophilic/zoo philic): not reported
Phenotypic resistance profile: not reported
Genotypic resistance profile: not reported
Method of mosquito collection: light and exit traps indoors in 6 rooms in 6 different randomly selected compounds per cluster, 1 night per month

Notes

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Villages were randomly assigned using a computerized algorithm</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Low risk</td>
<td>Villages were randomly assigned using a computerized algorithm</td>
</tr>
</tbody>
</table>
## Pinder 2015 (Continued)

<table>
<thead>
<tr>
<th>Bias Type</th>
<th>Risk Level</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blinding of participants and personnel (performance bias)</td>
<td>Low risk</td>
<td>Participants and personnel were not blinded to intervention.</td>
</tr>
<tr>
<td>Incidence of malaria</td>
<td></td>
<td>For prevalence, risk of bias is low as every participant had their blood taken</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias)</td>
<td>Low risk</td>
<td>For prevalence, risk of bias was low as every participant had their blood taken</td>
</tr>
<tr>
<td>Prevalence of malaria</td>
<td>Low risk</td>
<td>For prevalence, risk of bias was low as every participant had their blood taken. Slide microscopists and their supervisors were blinded to the identity and intervention status of the participants</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>Unclear risk</td>
<td>Unclear risk of bias for incidence due to self-reporting of sickness before confirmation by microscopy, an objective assessment</td>
</tr>
<tr>
<td>Incidence of malaria</td>
<td></td>
<td>For prevalence, risk of bias was low as every participant had their blood taken. Observer bias was reduced where feasible. Slide microscopists and their supervisors were blinded to the identity and intervention status of the participants</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>Low risk</td>
<td>For prevalence, risk of bias was low as every participant had their blood taken. Observer bias was reduced where feasible. Slide microscopists and their supervisors were blinded to the identity and intervention status of the participants</td>
</tr>
<tr>
<td>Prevalence of malaria</td>
<td>Low risk</td>
<td>For prevalence, risk of bias was low as every participant had their blood taken. Observer bias was reduced where feasible. Slide microscopists and their supervisors were blinded to the identity and intervention status of the participants</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>Low risk</td>
<td>Incomplete outcome data were minimal and similar between intervention arms. Attrition between 2010 and 2011 accounted for by topping up cohort with newborn children (312 in LLIN + IRS arm; 324 in LLIN-only arm)</td>
</tr>
<tr>
<td>All outcomes</td>
<td></td>
<td>The study protocol reported on each outcome as stated in the clinical trials register (note: retrospectively registered)</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Low risk</td>
<td>The study protocol reported on each outcome as stated in the clinical trials register (note: retrospectively registered)</td>
</tr>
<tr>
<td>Recruitment bias</td>
<td>Low risk</td>
<td>Cohort of children were randomly selected.</td>
</tr>
<tr>
<td>Baseline imbalance</td>
<td>Low risk</td>
<td>Baseline data were displayed and similar.</td>
</tr>
<tr>
<td>Loss of clusters</td>
<td>Low risk</td>
<td>No clusters were lost.</td>
</tr>
<tr>
<td>Incorrect analysis</td>
<td>Low risk</td>
<td>Adjustment for clustering was done.</td>
</tr>
<tr>
<td>Comparability with RCTs randomizing participants</td>
<td>Low risk</td>
<td>Because the intervention was expected to have community level impact as well as individual impact, cRCTs are the most appropriate study design to capture this</td>
</tr>
<tr>
<td>Other bias</td>
<td>Low risk</td>
<td>No other biases.</td>
</tr>
</tbody>
</table>
### Protopopoff 2018

#### Methods

**Study design:** cRCT with 4 intervention arms using a 2 × 2 factorial design  
- arm 1: standard LLIN (Olyset Net)  
- arm 2: standard LLIN (Olyset Net) + IRS  
- arm 3: pyrethroid net + synergist PBO (Olyset Plus)  
- arm 4: pyrethroid net + synergist PBO (Olyset Plus) + IRS  

**Therefore, there were 2 comparisons for this review:** arm 1 versus arm 2, and arm 3 versus arm 4  
**Unit of allocation:** clusters comprised from 40 villages  
**Number of units:** 48 clusters randomized into 4 arms equally  
**Outcome assessment/surveillance type:** cross-sectional surveys of children aged 0.5-14 years were done to determine the prevalence of *Plasmodium* spp infection. The main endpoint for assessment of the IRS was 9 months postintervention. Up to 3 children from 55 households with eligible participants per cluster were randomly selected for each survey  
**Length of follow-up:** originally planned for 18 months (1 January 2015 to 30 June 2016) but was subsequently extended to 24 months (1 January 2014 to 31 December 2016)  
**Adjustment for clustering:** yes

#### Participants

**Number of participants:** at the primary endpoint for assessment of the IRS, the number of children recruited were 933 in arm 1, 877 in arm 2, 883 in arm 3, and 969 in arm 4  
**Population characteristics:**  
- total population in core and buffer areas ranged from 31,138 to 38,081  
- total population in the core area of the clusters between 14,845 and 16,358  
**Withdrawal and loss to follow-up:** a fresh cohort was recruited for each cross-sectional survey and ITT analysis was conducted

#### Interventions

**IRS:**  
- Active ingredient and dosage: pirimiphos-methyl at the recommended dosage 1 g/m²  
- Formulation: 30% capsule suspension (Actellic 300CS)  
- Frequency of spraying: once in February 2015  
- Coverage: per cluster (%): 94% (95% CI 92% to 96%) in arm 2 and 94% (95% CI 87% to 97%) in arm 4  
- Buffer size between clusters: minimum outer buffer zone of 300 m. Only the inner core area was used for the measurement of study outcomes  
**ITN:**  
- Active ingredient and dosage: permethrin 2% w/w (Olyset Net) and permethrin 2% (Olyset Plus) and PBO 1% w/w  
- Coverage: 9 months postintervention, coverage defined as household owning ≥ 1 LLIN (study LLIN or any other LLIN) was 98% (95% CI 96% to 99%) in arm 2 and 98% (95% CI 95% to 99%) in arm 4  
- Compliance: at 9 months postintervention, compliance defined as residents declaring to use an LLIN the previous night (study LLIN or any other LLIN) was 76% (95% CI 70% to 80%) in arm 2 and 77% (95% CI 70% to 83%) in arm 4  
**Control:** ITN only as above  
- Coverage: at 9 months postintervention, coverage defined as household owning ≥ 1 LLIN (study LLIN or any other LLIN) was 97% (95% CI 93% to 99%) in arm 1 and 98% (95% CI 97% to 99%) in arm 3  
- Compliance: at 9 months postintervention, compliance defined as residents declaring to
use a LLIN the previous night (study LLIN or any other LLIN) was 80% (95% CI 75% to 85%) in arm 1 and 78% (95% CI 73% to 82%) in arm 3

**Cointerventions:** none reported

<table>
<thead>
<tr>
<th>Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>● Prevalence of <em>Plasmodium</em> spp infection</td>
</tr>
<tr>
<td>● Proportion of children with moderate-to-severe anaemia (defined as haemoglobin &lt; 8 g/dL)</td>
</tr>
<tr>
<td>● EIR defined as the mean number of infective mosquito bites per household per month</td>
</tr>
<tr>
<td>● Adult mosquito density per night per household</td>
</tr>
</tbody>
</table>

**Location profile**

**Study location:** Northwest Tanzania, Muleba District, Kagera Region, the study area comprised 29,365 households and a population of 135,900 people

**Malaria endemicity:** perennial with peaks after the rainy season. Rainfall occurs in 2 seasons: the "short rains" in October-December (mean monthly rainfall 160 mm) and the "long rains" in March-May (mean monthly rainfall 300 mm)

**EIR:** not measured at baseline

**Population proximity/density:** not reported

**Plasmodium spp:** *P. falciparum*

**Vector profile**

**Primary (and secondary) vector species:** *An. gambiae* s.s. (*An. arabiensis* and *An. funestus*)

**Vector behaviour** (nature, stability, adult habitat, peak biting times, exophilic/endophilic, exophagic/endophagic, anthropophilic/zoophilic): not reported

**Phenotypic resistance profile:** *An. gambiae* s.l. had high levels of resistance to pyrethroids.

**Genotypic resistance profile:** the *Vgsc* gene mutation was found in all tested *An. gambiae* s.l. with co-occurrence of *Vgsc-1014F* and *Vgsc-1014S* in 22 (9%) of 234 *An. gambiae* s.l. mosquitoes. No mutation was found in the 247 *An. arabiensis* tested.

**Method of mosquito collection:** mosquito surveillance was done from March 2015 to December 2016, in each cluster by a project field assistant for 1 night per month in 7 randomly selected houses per cluster using CDC Miniature Light Trap Model 512 (John W Hock Company, USA)

**Notes**

**Risk of bias**

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>During each survey, we randomly sampled 55 households with children aged 6 months to 14 years from the core area of each cluster using the census lists</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Low risk</td>
<td>The inhabitants of each cluster to the type of LLINs received. The 2 types of nets were of similar colour and shape, and only distinguishable by label codes and coloured thread inserted during manufacture. Additionally, field staff who took blood samples</td>
</tr>
</tbody>
</table>
in the cross-sectional surveys were masked to the study arms the clusters were assigned to.
It was not possible to blind either the investigators or the participants to the treatment allocation of IRS but we do not feel this would impact the outcome.

<table>
<thead>
<tr>
<th>Source of Bias</th>
<th>Risk of Bias</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blinding of participants and personnel (performance bias)</td>
<td>Low risk</td>
<td>This outcome was not measured.</td>
</tr>
<tr>
<td>Incidence of malaria</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Field staff who took blood samples in the cross-sectional surveys were masked to the study arms the clusters were assigned to. It was not possible to mask either the investigators who assessed the blood samples or the participants to the treatment allocation of IRS but we do not consider this would impact the outcome which was assessed by RDT (an objective test).</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>Low risk</td>
<td>This outcome was not measured.</td>
</tr>
<tr>
<td>Incidence of malaria</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Field staff who took blood samples in the cross-sectional surveys were masked to the study arms the clusters were assigned to. It was not possible to blind either the investigators or the participants to the treatment allocation of IRS but we do not feel this would impact the outcome which was assessed by RDT (an objective test).</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>Low risk</td>
<td>A new cohort of children was used for each cross-sectional survey.</td>
</tr>
<tr>
<td>All outcomes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Low risk</td>
<td>The study protocol reported each outcome as stated in the clinical trials register (note: retrospectively registered).</td>
</tr>
<tr>
<td>Recruitment bias</td>
<td>Low risk</td>
<td>Cohort of children were randomly selected.</td>
</tr>
<tr>
<td>Baseline imbalance</td>
<td>Low risk</td>
<td>Baseline data was displayed. No significant differences at baseline for outcomes the study assessed.</td>
</tr>
<tr>
<td>Loss of clusters</td>
<td>Low risk</td>
<td>No clusters were lost.</td>
</tr>
</tbody>
</table>
### Incorrect analysis
- Low risk
- Adjustment for clustering was done.

### Comparability with RCTs randomizing participants
- Low risk
- Because the intervention is expected to have community level impact as well as individual impact, cRCTs are the most appropriate study design to capture this

### Other bias
- Low risk
- No other biases.

## West 2014

### Methods
- **Study design:** cRCT with 2 intervention arms
- **Unit of allocation:** clusters (villages)
- **Number of units:** 25 randomized villages in each arm. A subset of 20 villages per arm was used for entomological assessment
- **Outcome assessment/surveillance type:** see below in 'Outcomes' section
- **Length of follow-up:** 3 postintervention cross-sectional household surveys were undertaken in 2012. Survey A (23 February to 31 March) was after the short rainy season and 2 months after the first spray round. Survey B (25 June to 31 July) was after the long rainy season, 6 months after the first spray round, and 2 months after the second spray round. Survey C (25 October to 4 December) was 6 months after the second spray round and 10 months after the first. Baseline surveys were conducted in 2011 during the same periods as surveys A and B
- **Adjustment for clustering:** yes

### Participants
- **Number of participants:** for each of the survey, a different number of participants were used in each cohort
  - Survey A: 2192 children in control arm, 2348 in intervention arm
  - Survey B: 2045 children in control arm, 2207 in intervention arm
  - Survey C: 2101 children in control arm, 2303 in intervention arm
- **Population characteristics:** cohort of children aged 0.5-14 years, villages had to be sprayed with IRS in the baseline year
- **Withdrawal and loss to follow-up:** 82.2% to 84.4% of intervention participants tested in each survey. 78.3% to 80.8% of control participants tested

### Interventions
- **IRS:**
  - Active ingredient and dosage: bendiocarb 400 mg/m²
  - Formulation: 80% wettable powder
  - Frequency of spraying: 2 rounds of spraying (December 2011 to January 2012) and (April 2012 to May 2012), timed to precede the peak in malaria cases that normally occurs at the end of each rainy season
  - Coverage: survey A: 92.1% (88.4% to 94.7%) (1215); survey B: 89.5% (84.0% to 93.2%) (1138); survey C: 89.3% (83.6% to 93.2%) (1209)
  - Buffer size between clusters: each village was divided into a core surveillance area consisting of ≥ 200 houses and approximately 1 km radius, where the surveys were conducted, and an outer buffer zone of approximately 1 km width which also received treatment but in which no outcome monitoring was done
- **ITN:**
Active ingredient and dosage: permethrin 2% w/w (Olyset Net)
Coverage measured as % of households with ≥ 1 ITN per sleeping space: survey A: 57.2 (range 53.6-60.7) (1215); survey B: 57.4 (range 54.0-60.9) (1142); survey C: 56.8 (range 51.7-61.8) (1211)
Coverage measured as % of households with ≥ 1 ITN: survey A: 89.0 (range 87.1-90.6) (1216); survey B: 88.2 (range 85.7-90.3) (1142); survey C: 83.8 (range 79.9-87.1) (1211)
Compliance measured as % of study children that reported sleeping under an ITN the night previous to the survey:
survey A: 53.0 (range 47.5-58.3) (2349); survey B: 44.1 (range 39.2-49.2) (2207); survey C: 36.1 (range 31.0-41.5) (2303)
**Control:** ITN only as above
Coverage measured as % of households with ≥ 1 ITN per sleeping space: survey A: 52.2 (range 47.8-56.5) (1178); survey B: 51.6 (range 47.0-56.0) (1094); survey C: 52.8 (range 47.6-58.0) (1168)
Coverage measured as % of households with ≥ 1 ITN: survey A: 85.8 (range 83.7-87.7) (1177); survey B: 82.5 (range 78.7-85.7) (1096); survey C: 78.2 (range 74.3-81.6) (1170)
Compliance measured as % of study children that reported sleeping under an ITN the night previous to the survey: survey A: 46.6 (range 41.7-51.6) (2193); survey B: 40.7 (range 34.7-47.0) (2045); survey C: 36.0 (range 29.8-42.6) (2101)
**Cointerventions:** none reported

### Outcomes

| **P falciparum** parasite rate in children aged 0.5-14 years, 80 households in each cluster. Up to 3 children per household selected. Aimed for a mean of 80 children per cluster. Tested with RDT (Carestart (Pan) Malaria, DiaSys) |
| Anaemia in children aged < 5 years |
| Mean haemoglobin in children aged < 5 years. Tested with HemoCue Hb 201+ (Aktebolaget Leo Diagnostics) |
| EIR: 20/25 clusters per arm were monitored for 1 night each month from April 2011 to December 2012. 8 randomly selected houses in each cluster |

### Location profile

**Study location:** Northwest Tanzania, Muleba District, Kagera Region, the study area included 68,108 households at an altitude of 1100-1600 m above sea level. Rainfall occurred in 2 seasons: the ‘short rains’ in October-December (mean monthly rainfall 160 mm) and the ‘long rains’ in March-May (mean monthly rainfall 300 mm)

**Malaria endemicity:** perennial with peaks after the rainy season

**EIR:** baseline characteristics measured by the study reported a mean per month in the control arm of 1.1 (range 0.4-2.8) and 1.3 (range 0.4-4.4) in the intervention arm

**Population proximity/density:** not reported

**Plasmodium spp:** P falciparum

### Vector profile

**Primary (and secondary) vector species:** An gambiae s.s. and An arabiensis

**Vector behaviour (nature, stability, adult habitat, peak biting times, exophilic/endophilic, exophagic/endophagic, anthropophilic/zoophilic):** not reported

**Phenotypic resistance profile:** resistance to pyrethroids in An gambiae s.s.

**Genotypic resistance profile:** not reported

**Method of mosquito collection:** CDC light traps indoors
<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Quote: “Twenty-five clusters were randomly allocated to receive IRS…” Comment: 200,000 random allocations were generated. 1 allocation was randomly selected from the list of these with no intraclass cluster dependence on key variables</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Low risk</td>
<td>Allocation concealment was a low risk of bias considering the computer-randomized allocation</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias)</td>
<td>Low risk</td>
<td>Outcome not reported.</td>
</tr>
<tr>
<td>Incidence of malaria</td>
<td></td>
<td>Participants could not be blinded to the control and intervention. However, the outcomes recorded were objective and at low risk of being affected by intervention arm knowledge</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>Low risk</td>
<td>Outcome not reported.</td>
</tr>
<tr>
<td>Incidence of malaria</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>Low risk</td>
<td>Outcome assessors were not blinded to the control and intervention. However, the outcomes recorded were objective measurements (using RDTs, and standardized mosquito traps)</td>
</tr>
<tr>
<td>Prevalence of malaria</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>Low risk</td>
<td>ITT was done, balanced numbers in both arms.</td>
</tr>
<tr>
<td>All outcomes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Low risk</td>
<td>Outcomes reported match those in the registered protocol, but children aged 6 months to 10 years rather than 14 years was reported in the trial protocol</td>
</tr>
<tr>
<td>Recruitment bias</td>
<td>Low risk</td>
<td>Cohort of children were randomly selected.</td>
</tr>
</tbody>
</table>
Baseline imbalance | Low risk | Baseline characteristics were presented for both study arms and showed similarity across key characteristics
---|---|---
Loss of clusters | Low risk | 1 cluster was assigned the wrong intervention and then dropped. Sensitivity analysis was done to show this did not impact the outcome
Incorrect analysis | Low risk | Adjustment for clustering was done.
Comparability with RCTs randomizing participants | Low risk | Because the intervention is expected to have community level impact as well as individual impact, cRCTs are the most appropriate study design to capture this
Other bias | Low risk | No other biases.

Abbreviations: *Anopheles arabiensis*: *An* arabiensis; *An funestus*: *Anopheles* funestus; *An gambiae*: *Anopheles* gambiae; cRCT: cluster randomized controlled trial; CSP: circumsporozoite protein; CTPS: carbamate-treated plastic sheeting; DDT: dichloro-diphenyl-trichloroethane; EIR: entomological inoculation rate; ELISA: enzyme-linked immunosorbent assay; IRD-CREC: Institut de Recherche pour le Développement Centre de Recherches Entomologiques de Cotonou; IRS: indoor residual spraying; ITN: insecticide-treated net; ITT: intention to treat; LLIN: long-lasting insecticidal mosquito net; *P falciparum*: *Plasmodium falciparum*; *P vivax*: *Plasmodium vivax*; RCT: randomized controlled trial; RDT: rapid diagnostic test; TLLIN: targeted long-lasting insecticidal mosquito nets; ULLIN: universal long-lasting insecticidal mosquito nets; WHO: World Health Organization.

**Characteristics of excluded studies** [ordered by study ID]

<table>
<thead>
<tr>
<th>Study</th>
<th>Reason for exclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abeiku 2014</td>
<td>Study design did not meet inclusion criteria</td>
</tr>
<tr>
<td>Bekele 2012</td>
<td>Study design did not meet inclusion criteria</td>
</tr>
<tr>
<td>Diallo 2015</td>
<td>Study design did not meet inclusion criteria</td>
</tr>
<tr>
<td>Fullman 2013</td>
<td>Study design did not meet inclusion criteria</td>
</tr>
<tr>
<td>Gari 2016</td>
<td>Study design did not meet inclusion criteria</td>
</tr>
<tr>
<td>Ginnig 2016</td>
<td>Study design did not meet inclusion criteria</td>
</tr>
<tr>
<td>Hamel 2011</td>
<td>Study design did not meet inclusion criteria</td>
</tr>
<tr>
<td>Study</td>
<td>Notes</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>--------------------------------------------</td>
</tr>
<tr>
<td>Katureebe 2016</td>
<td>Study design did not meet inclusion criteria</td>
</tr>
<tr>
<td>Kitau 2015</td>
<td>Duplicate (data from West 2014)</td>
</tr>
<tr>
<td>Lyimo 1991</td>
<td>Study design did not meet inclusion criteria</td>
</tr>
<tr>
<td>Matowo 2015</td>
<td>Study design did not meet inclusion criteria</td>
</tr>
<tr>
<td>Pinder 2011</td>
<td>Duplicate (study protocol of Pinder 2015)</td>
</tr>
<tr>
<td>Pinder 2012</td>
<td>Duplicate (conference abstract of Pinder 2015)</td>
</tr>
<tr>
<td>Protopopoff 2007a</td>
<td>Study design did not meet inclusion criteria</td>
</tr>
<tr>
<td>Protopopoff 2007b</td>
<td>Study design did not meet inclusion criteria</td>
</tr>
<tr>
<td>Protopopoff 2015a</td>
<td>Duplicate (conference abstract of West 2014)</td>
</tr>
<tr>
<td>Protopopoff 2015b</td>
<td>Duplicate (data from West 2014)</td>
</tr>
<tr>
<td>West 2012</td>
<td>Duplicate (conference abstract of West 2014)</td>
</tr>
<tr>
<td>West 2015</td>
<td>Study design did not meet inclusion criteria</td>
</tr>
<tr>
<td>Zhou 2013</td>
<td>Study design did not meet inclusion criteria</td>
</tr>
</tbody>
</table>

**Characteristics of studies awaiting assessment [ordered by study ID]**

### Chaccour 2018

**Methods**

- **Study design:** cRCT with 2 intervention arms
- **Study status:** ongoing
- **Unit of allocation:** villages
- **Number of units:** 43 clusters per arm
- **Outcome assessment/surveillance type:**
  - Community malaria incidence measured through active monthly parasitological surveys in participating households. 18 children from each cluster aged 6-59 months at time of enumeration recruited. Parasitaemia confirmed with RDT;
  - Incidence rates at the health facility level measured via passive surveillance.
- **Length of follow-up:** September 2016 to December 2018
- **Adjustment for clustering:** yes

**Participants**

- **Number of participants:** cohort of 784 children per arm aged 6-59 months were recruited for monthly active case detection. For each cross-sectional survey, an independent sample of 770 participants (385 children aged 6-71 months and 385 children aged ≥ 60 months) were included
- **Population characteristics:** 162,188 participants, with 31,927 (19.7%) under 5 years of age
Withdrawal and loss to follow-up: not reported

**Interventions**

**IRS:**
Active ingredient and dosage: pirimiphos-methyl at the recommended dosage of 1 g/m²
Formulation: 30% capsule suspension (Actellic 300CS)
Frequency of spraying: yearly
Coverage: aimed for universal coverage
Buffer size between clusters: each cluster had an internal buffer zone of ≥ 1km defined around each cluster's core area, and cohort members were only selected from core areas

**ITN:**
Active ingredient and dosage: nets used at the time from mass distribution campaigns
Coverage: not reported
Compliance: not reported
Control: ITN only as above
Cointerventions: none reported

**Outcomes**

**Primary:**
Malaria cases averted in children aged 6-59 months at the community level by adding IRS (community incidence)
Cost per malaria case averted in children aged 6-59 months at the community level by adding IRS
Malaria case averted in children aged 6-59 months at the health facility level by adding IRS (health facility incidence)
Cost per malaria case averted in children aged 6-59 months at the health facility level by adding IRS

**Secondary:**
Vector densities, human biting rates, sporozoite rates, indoor and outdoor feeding behaviours, prevalence and intensity of resistance to pyrethroids, and estimates of EIR as measured or estimated through entomological surveillance
Changes in community-based parasite prevalence
Incremental impact of combining IRS with LLINs, including assessment of the impact of new nets in year 2
Correlation between incidence at community and health facility levels
Correlation between incidence (community and health facility) and prevalence
Changes in malaria prevention methods including net use and in health-seeking behaviour

**Location profile**

**Primary**
Study location: Mopeia is a district in Zambezia, 1 of the most impoverished provinces of Mozambique. Carried out in all of Mopeia's villages
Malaria endemicity: highly endemic
EIR: not reported
Population proximity/density: not reported
Plasmodium spp: *P. falciparum*

**Primary (and secondary) vector species:** *An. gambiae* s.s. and *An. funestus* s.s. although *An. arabiensis* is present as well
Vector behaviour (nature, stability, adult habitat, peak biting times, exophilic/endophilic, exophagic/endophagic, anthropophilic/zoophilic): not reported
Phenotypic resistance profile: data from January 2015 in the neighbouring districts of Mocuba and Morrumbala show pyrethroid resistance (mortality 24 hours after deltamethrin WHO tube test: 52% in Mocuba and 34% in Morrumbala; mortality after lambda-cyhalothrin: 40% in Mocuba and 33% in Morrumbala) in the local *An. gambiae* s.l. population.
Genotypic resistance profile: not reported
Method of mosquito collection: 8 households in each cluster from a subset of 5 villages per arm used light traps
and human landing catches. Monitoring took place on 3 consecutive nights every month leading to 240 collections per month.

### Notes

**Deressa 2016**

#### Methods

**Study design:** cRCT with 4 intervention arms:
- LLIN + IRS
- LLINs alone
- IRS alone
- control

**Study status:** ongoing

**Unit of allocation:** villages

**Number of units:** 44 clusters per arm, with each cluster comprised of approximately 35 households (about 175 people)

**Outcome assessment/surveillance type:** malaria incidence based on the results of the RDTs in people with a fever or history of fever attending health posts by passive case detection. Community-based surveys were conducted each year to assess anaemia among children aged 5-59 months. In addition, community-based malaria prevalence surveys were conducted each year on a representative sample of households during the main transmission season.

**Length of follow-up:** 119 weeks from September 2014 to January 2017

**Adjustment for clustering:** not reported

#### Participants

**Number of participants:** 34,548 total

**Population characteristics:** not reported

**Withdrawal and loss to follow-up:** not reported

#### Interventions

**The relevant comparison for this review is LLIN + IRS versus LLINs alone**

**IRS:**
- Active ingredient and dosage: propoxur 2 g/m²
- Formulation: 50% water-dispersible powder
- Frequency of spraying: yearly
- Coverage: aimed for 80% coverage as per WHO recommendations
- Buffer size between clusters: not reported

**ITN:**
- Active ingredient and dosage: deltamethrin 55 mg (PermaNet 2.0)
- Coverage: not reported
- Compliance: not reported

**Control:** ITN only as above

**Cointerventions:** none reported

#### Outcomes

**Primary:**
- Malaria incidence

**Secondary:**
- Anaemia in children
- Malaria prevalence
- Mosquito adult density
- Sporozoite rate
- Changes in insecticide resistance, both phenotype and genotype
Location profile

**Study location:** study was carried out in the Adami Tullu part of the Adami Tullu-Jiddo-Kombolcha woreda in the East Shewa Zone of the Oromia Regional State in Ethiopia. The capital of the district, Zeway (or Batu), has a latitude and longitude of 7°56’N 38°42’E with an elevation of 1640 m above sea level. It is located approximately 160 km south of Addis Ababa. The district is set in the Great Rift Valley in south-central Ethiopia, with altitudes ranging from 1500 m to 2300 m. For villages to be included in the trial, they had to have a relatively easy access, relatively higher malaria transmission, and located within 5 km from Lake Zeway.

**Malaria endemity:** seasonal and unstable. The main malaria transmission season occurs between September and December each year following the heavy rainfall between July and August, whereas the smaller peak occurs during May and June each year following small rains during March and April.

**EIR:** not reported.

**Population proximity/density:** not reported.

**Plasmodium spp:** P. falciparum and P. vivax.

Vector profile

**Primary (and secondary) vector species:** An. arabiensis and An. pharoensis.

**Vector behaviour (nature, stability, adult habitat, peak biting times, exophilic/endophilic, exophagic/endophagic, anthropophilic/zoophilic):** not reported.

**Phenotypic resistance profile:** not reported.

**Genotypic resistance profile:** not reported.

**Method of mosquito collection:** 16 villages (4 per arm) were randomly selected for entomological study, in which indoor host-seeking mosquitoes were collected by CDC light traps from 4 houses per arm, indoor resting mosquitoes from 16 houses per arm using pyrethrum spray collection and outdoor resting mosquitoes from 4 artificial pit shelters per arm of the study.

Phenotypic insecticide resistance was monitored annually throughout the study period using standard WHO tube tests. Insecticides used in this test were pyrethroids (deltamethrin, alpacypermethrin, permethrin, and lambdacyhalothrin) and the carbamates (bendiocarb and propoxur). Resistance intensity was quantified to assess any change in resistance. Molecular and biochemical analyses were used to identify potential insecticide resistance mechanisms.

Notes

Hamainza 2016

**Methods**

**Study design:** cluster stepped-wedge design RCT; the study assessed the impact of 4 different IRS insecticide formulations.

**Study status:** completed.

**Unit of allocation:** village or groups of villages.

**Number of units:** 14 units with mixed interventions.

**Outcome assessment/surveillance type:**

- Active monthly parasitological surveys in participating households. Participants were encouraged to seek care through passively offered diagnosis and treatment services in-between surveys. Parasitaemia confirmed with RDT (ICT Malaria Pf. cassette test).
- Entomological observations were made in 15 households in each cluster. Additionally, human landing catches were conducted both indoors and outdoor.

**Length of follow-up:** 29 months in Luangwa and 26 months in Nyimba, starting from January.

**Adjustment for clustering:** yes.
| Participants | Number of participants: 25,354 at the start of the study stated in population characteristics; however, figure 2 suggested 84,275  
| Population characteristics: out of these participants, 29% (7412) were children under the age of 5 years. The overall cluster populations ranged from 1158 to 3429  
| Withdrawal and loss to follow-up: Figure 2 in the paper suggested many participants withdrew, no ITT analysis stated |
| Interventions | IRS:  
| Active ingredient, dosage, formulation and coverage:  
| • deltamethrin, wettable granule formulation, 82%  
| • lambdacyhalothrin, capsule suspension, 61%  
| • pirimiphos methyl, emulsifiable concentrate, 53%  
| • pirimiphos methyl, capsule suspension, 69%  
| Frequency of spraying:  
| • October 2010: deltamethrin (clusters 4, 5, 6, and 7); Control (1, 2, 3, 8, 9, 10, 11, 12, 13, and 14)  
| • October 2011: pirimiphos EC (2, 4, 5, 9, 11, and 13); lambdacyhalothrin (6, 7); Control (1, 3, 8, 10, and 12)  
| • November 2012: pirimiphos CS (8, 9, 10, 12, and 14); February 2013: pirimiphos EC (2, 4, and 5); Lambdacyhalothrin (6 and 7); Control (1, 2, 3, 11, and 13)  
| Coverage: in the first 1-6 months' post IRS implementation (range 0-100%; mean 29.4%)  
| Buffer size between clusters: not reported  
| ITN: no mass distribution took place as part of the study; however, ITN use was already high (LLIN use in the first 1-6 months' post IRS implementation across all clusters in both arms (range 6.6-100%, mean 68.2%))  
| Control: ITN as above and areas that had not yet received spraying during the study period and those for which the last spray round began more than 12 months ago  
| Cointerventions: intermittent preventive therapy |
| Outcomes | Primary:  
| Diagnostic positivity for malaria infection, expressed as the proportion of RDT-tested people who were found to be positive  
| Secondary:  
| Indoor-outdoor distribution of human exposure to *An. funestus* bites measured as bites per person per hour |
| Location profile | Study location: Luangwa located in Lusaka and Nyimba located in Eastern provinces, of the Republic of Zambia. Predominantly rural  
| Malaria endemicity: perennial  
| EIR: 70 (for non-users of LLINs)  
| Population proximity/density: not reported  
| *Plasmodium* spp: *P. falciparum* |
| Vector profile | Primary (and secondary) vector species: *An. funestus*  
| Vector behaviour (nature, stability, adult habitat, peak biting times, exophilic/endophilic, exophagic/endophagic, anthropophilic/zoophilic): not reported  
| Phenotypic resistance profile: F1 generation from wild-caught mosquitoes were exposed to standard WHO susceptibility tests using insecticide impregnated papers for the duration of the study (2010-2013). Throughout the study period, *An. funestus* were consistently susceptible to both malathion and DDT (100% mortality) in both Luangwa and Nyimba. Moderate resistance to deltamethrin that increased to high resistance in both sites during the study period. Lambdacyhalothrin showed a similar pattern but was only measured in Luangwa  
| Genotypic resistance profile: not reported |
Method of mosquito collection: light traps and Ifakara tent traps. Each house was visited once per month for mosquito trapping. Light traps were placed at the foot end of an occupied sleeping space covered with an LLIN, hanging approximately 1.5 m above the floor. A tent trap was placed immediately outside, approximately 5 m away from the house. Traps were set up in the evenings and collection of the captured mosquitoes was done in the early morning by aspiration. Additionally, human landing catches were conducted both indoors and outdoors from 18.00 to 06.00 hours.

Notes

Abbreviations: *An*: Anopheles; CDC: Centers for Disease Control and Prevention; cRCT: cluster randomized controlled trial; DDT: dichloro-diphenyl-trichlorethane; EIR: entomological inoculation rate; ICT: immunochromatographic diagnostic test; IRS: indoor residual spraying; ITN: insecticide-treated net; ITT: intention to treat; LLIN: long-lasting insecticidal mosquito net; RCT: randomized controlled trial; RDT: rapid diagnostic test; WHO: World Health Organization.
### DATA AND ANALYSES

Comparison 1. Non-pyrethroid-like indoor residual spraying (IRS) plus insecticide-treated nets (ITNs) versus ITNs alone

<table>
<thead>
<tr>
<th>Outcome or subgroup title</th>
<th>No. of studies</th>
<th>No. of participants</th>
<th>Statistical method</th>
<th>Effect size</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Malaria incidence</td>
<td>2</td>
<td></td>
<td>Rate ratio (Random, 95% CI)</td>
<td>0.93 [0.46, 1.86]</td>
</tr>
<tr>
<td>2 Malaria parasite prevalence</td>
<td>4</td>
<td></td>
<td>Risk Ratio (Random, 95% CI)</td>
<td>0.67 [0.35, 1.28]</td>
</tr>
<tr>
<td>3 Malaria parasite prevalence (net usage subgroup analysis)</td>
<td>4</td>
<td></td>
<td>Risk Ratio (Random, 95% CI)</td>
<td>0.67 [0.35, 1.28]</td>
</tr>
<tr>
<td>3.1 Net usage ≥ 50%</td>
<td>2</td>
<td></td>
<td>Risk Ratio (Random, 95% CI)</td>
<td>0.47 [0.33, 0.67]</td>
</tr>
<tr>
<td>3.2 Net usage &lt; 50%</td>
<td>2</td>
<td></td>
<td>Risk Ratio (Random, 95% CI)</td>
<td>0.87 [0.34, 2.22]</td>
</tr>
<tr>
<td>4 Anaemia prevalence</td>
<td>2</td>
<td></td>
<td>Risk Ratio (Random, 95% CI)</td>
<td>0.46 [0.18, 1.20]</td>
</tr>
<tr>
<td>5 kdr allelic frequency</td>
<td>1</td>
<td></td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>Subtotals only</td>
</tr>
<tr>
<td>5.1 Sensitivity analysis with an estimated intracluster correlation coefficient (ICC) of 0.01</td>
<td>1</td>
<td>107</td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>1.01 [0.86, 1.18]</td>
</tr>
<tr>
<td>5.2 Sensitivity analysis with an estimated ICC of 0.05</td>
<td>1</td>
<td>84</td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>0.99 [0.83, 1.18]</td>
</tr>
<tr>
<td>5.3 Sensitivity analysis with an estimated ICC of 0.1</td>
<td>1</td>
<td>67</td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>1.01 [0.83, 1.22]</td>
</tr>
</tbody>
</table>

Comparison 2. Pyrethroid-like indoor residual spraying (IRS) plus insecticide-treated nets (ITNs) versus ITNs alone

<table>
<thead>
<tr>
<th>Outcome or subgroup title</th>
<th>No. of studies</th>
<th>No. of participants</th>
<th>Statistical method</th>
<th>Effect size</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Malaria incidence</td>
<td>2</td>
<td></td>
<td>Rate ratio (Random, 95% CI)</td>
<td>1.07 [0.80, 1.43]</td>
</tr>
<tr>
<td>2 Malaria parasite prevalence</td>
<td>3</td>
<td></td>
<td>Risk Ratio (Random, 95% CI)</td>
<td>1.11 [0.86, 1.44]</td>
</tr>
<tr>
<td>3 Anaemia prevalence</td>
<td>1</td>
<td></td>
<td>Risk Ratio (Random, 95% CI)</td>
<td>1.12 [0.89, 1.40]</td>
</tr>
</tbody>
</table>
Analysis 1.1. Comparison 1 Non-pyrethroid-like indoor residual spraying (IRS) plus insecticide-treated nets (ITNs) versus ITNs alone, Outcome 1 Malaria incidence.

Review: Indoor residual spraying for preventing malaria in communities using insecticide-treated nets

Comparison: 1 Non-pyrethroid-like indoor residual spraying (IRS) plus insecticide-treated nets (ITNs) versus ITNs alone

Outcome: 1 Malaria incidence

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>log [Rate ratio] (SE)</th>
<th>Rate ratio (IV, Random, 95% CI)</th>
<th>Weight</th>
<th>Rate ratio (IV, Random, 95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Corbel 2012</td>
<td>0.2776 (0.1954)</td>
<td>1.32 [0.90, 1.94]</td>
<td>50.1%</td>
<td></td>
</tr>
<tr>
<td>Kafy 2017 (1)</td>
<td>-0.4308 (0.1991)</td>
<td>0.65 [0.44, 0.96]</td>
<td>49.9%</td>
<td></td>
</tr>
<tr>
<td><strong>Total (95% CI)</strong></td>
<td></td>
<td>100.0% 0.93 [0.46, 1.86]</td>
<td>100.0%</td>
<td></td>
</tr>
</tbody>
</table>

Heterogeneity: Tau² = 0.21; Chi² = 6.45, df = 1 (P = 0.01); I² = 84%
Test for overall effect: Z = 0.21 (P = 0.83)
Test for subgroup differences: Not applicable

(1) IRS with bendiocarb (years 2 % 3)
Analysis 1.2. Comparison 1 Non-pyrethroid-like indoor residual spraying (IRS) plus insecticide-treated nets (ITNs) versus ITNs alone, Outcome 2 Malaria parasite prevalence.

Review: Indoor residual spraying for preventing malaria in communities using insecticide-treated nets

Comparison: 1 Non-pyrethroid-like indoor residual spraying (IRS) plus insecticide-treated nets (ITNs) versus ITNs alone

Outcome: 2 Malaria parasite prevalence

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>log [Risk Ratio] (SE)</th>
<th>Risk Ratio</th>
<th>Weight</th>
<th>Risk Ratio (IV(Random,95% CI))</th>
</tr>
</thead>
<tbody>
<tr>
<td>Corbel 2012</td>
<td>0.277 (0.1214)</td>
<td></td>
<td>24.9 %</td>
<td>1.32 [1.04, 1.67]</td>
</tr>
<tr>
<td>Kafy 2017 (1)</td>
<td>-0.8858 (0.1971)</td>
<td></td>
<td>23.6 %</td>
<td>0.41 [0.28, 0.61]</td>
</tr>
<tr>
<td>Protopopoff 2018 (2)</td>
<td>-0.1681 (0.4679)</td>
<td></td>
<td>17.0 %</td>
<td>0.85 [0.34, 2.11]</td>
</tr>
<tr>
<td>Protopopoff 2018 (3)</td>
<td>-0.6463 (0.5423)</td>
<td></td>
<td>15.2 %</td>
<td>0.52 [0.18, 1.52]</td>
</tr>
<tr>
<td>West 2014</td>
<td>-0.6829 (0.3777)</td>
<td></td>
<td>19.3 %</td>
<td>0.51 [0.24, 1.06]</td>
</tr>
</tbody>
</table>

Total (95% CI) 100.0 % 0.67 [0.35, 1.28]

Heterogeneity: $\tau^2 = 0.42$; $\chi^2 = 28.95$, df = 4 ($P<0.00001$); $I^2 = 86$

Test for overall effect: $Z = 1.21$ ($P = 0.23$)

Test for subgroup differences: Not applicable

(1) IRS with bendiocarb (years 2 % 3)

(2) with pyrethroid-PBO net; estimated ICC of 0.01 used to adjust for clustering

(3) With pyrethroid ITN; estimated ICC of 0.01 used to adjust for clustering
### Analysis 1.3. Comparison 1 Non-pyrethroid-like indoor residual spraying (IRS) plus insecticide-treated nets (ITNs) versus ITNs alone, Outcome 3 Malaria parasite prevalence (net usage subgroup analysis).

**Review**: Indoor residual spraying for preventing malaria in communities using insecticide-treated nets

**Comparison**: 1 Non-pyrethroid-like indoor residual spraying (IRS) plus insecticide-treated nets (ITNs) versus ITNs alone

**Outcome**: 3 Malaria parasite prevalence (net usage subgroup analysis)

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>log [Risk Ratio] (SE)</th>
<th>Risk Ratio</th>
<th>Weight</th>
<th>Risk Ratio IV/Random,95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Net usage ≥ 50%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kafy 2017 (1)</td>
<td>-0.8858 (0.1971)</td>
<td></td>
<td>23.6%</td>
<td>0.41 [ 0.28, 0.61 ]</td>
</tr>
<tr>
<td>Protopopoff 2018 (2)</td>
<td>-0.6463 (0.5423)</td>
<td></td>
<td>15.2%</td>
<td>0.52 [ 0.18, 1.52 ]</td>
</tr>
<tr>
<td>Protopopoff 2018 (3)</td>
<td>-0.1681 (0.4679)</td>
<td></td>
<td>17.0%</td>
<td>0.85 [ 0.34, 2.11 ]</td>
</tr>
<tr>
<td><strong>Subtotal (95% CI)</strong></td>
<td></td>
<td></td>
<td>55.8%</td>
<td>0.47 [ 0.33, 0.67 ]</td>
</tr>
<tr>
<td>Heterogeneity: $\tau^2 = 0.00; Chi^2 = 2.05, df = 2 (P = 0.36); I^2 = 2%$</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect: $Z = 4.23 (P = 0.000023)$</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 Net usage &lt; 50%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Corbel 2012</td>
<td>0.277 (0.1214)</td>
<td></td>
<td>24.9%</td>
<td>1.32 [ 1.04, 1.67 ]</td>
</tr>
<tr>
<td>West 2014</td>
<td>-0.6829 (0.3777)</td>
<td></td>
<td>19.3%</td>
<td>0.51 [ 0.24, 1.06 ]</td>
</tr>
<tr>
<td><strong>Subtotal (95% CI)</strong></td>
<td></td>
<td></td>
<td>44.2%</td>
<td>0.87 [ 0.34, 2.22 ]</td>
</tr>
<tr>
<td>Heterogeneity: $\tau^2 = 0.38; Chi^2 = 5.85, df = 1 (P = 0.02); I^2 = 83%$</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect: $Z = 0.29 (P = 0.77)$</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Total (95% CI)</strong></td>
<td></td>
<td></td>
<td>100.0%</td>
<td>0.67 [ 0.35, 1.28 ]</td>
</tr>
<tr>
<td>Heterogeneity: $\tau^2 = 0.42; Chi^2 = 28.95, df = 4 (P&lt;0.0001); I^2 = 86%$</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect: $Z = 1.21 (P = 0.23)$</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for subgroup differences: $Chi^2 = 1.49, df = 1 (P = 0.22), I^2 = 33%$</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(1) IRS with bendiocarb (years 2 % 3)

(2) With pyrethroid ITN; estimated ICC of 0.01 used to adjust for clustering

(3) with pyrethroid-PBO net; estimated ICC of 0.01 used to adjust for clustering
Analysis 1.4. Comparison 1 Non-pyrethroid-like indoor residual spraying (IRS) plus insecticide-treated nets (ITNs) versus ITNs alone, Outcome 4 Anaemia prevalence.

Review: Indoor residual spraying for preventing malaria in communities using insecticide-treated nets

Comparison: 1 Non-pyrethroid-like indoor residual spraying (IRS) plus insecticide-treated nets (ITNs) versus ITNs alone

Outcome: 4 Anaemia prevalence

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>log [Risk Ratio] (SE)</th>
<th>Risk Ratio IV,Random,95% CI Weight</th>
<th>Risk Ratio IV,Random,95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Protopopoff 2018 (1)</td>
<td>-1.7804 (0.7034)</td>
<td>29.3 % 0.17 [ 0.04, 0.67 ]</td>
<td></td>
</tr>
<tr>
<td>Protopopoff 2018 (2)</td>
<td>0.162 (1.3019)</td>
<td>11.8 % 1.18 [ 0.09, 15.08 ]</td>
<td></td>
</tr>
<tr>
<td>West 2014</td>
<td>-0.46 (0.2996)</td>
<td>58.9 % 0.63 [ 0.35, 1.14 ]</td>
<td></td>
</tr>
<tr>
<td><strong>Total (95% CI)</strong></td>
<td></td>
<td>100.0 % 0.46 [ 0.18, 1.20 ]</td>
<td></td>
</tr>
</tbody>
</table>

Heterogeneity: Tau² = 0.31; Chi² = 3.37, df = 2 (P = 0.19); I² = 41%
Test for overall effect: Z = 1.59 (P = 0.11)
Test for subgroup differences: Not applicable

(1) With pyrethroid ITN; estimated ICC of 0.01 used to adjust for clustering
(2) with PBO pyrethroid net; estimated ICC of 0.01 used to adjust for clustering

(Draft)
## Analysis 1.5. Comparison 1 Non-pyrethroid-like indoor residual spraying (IRS) plus insecticide-treated nets (ITNs) versus ITNs alone, Outcome 5 kdr allelic frequency

**Review:** Indoor residual spraying for preventing malaria in communities using insecticide-treated nets

**Comparison:** 1 Non-pyrethroid-like indoor residual spraying (IRS) plus insecticide-treated nets (ITNs) versus ITNs alone

**Outcome:** 5 kdr allelic frequency

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>IRS + ITNs n/N</th>
<th>ITNs only n/N</th>
<th>Risk Ratio M-H,Fixed,95% CI</th>
<th>Weight</th>
<th>Risk Ratio M-H,Fixed,95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Sensitivity analysis with an estimated intracluster correlation coefficient (ICC) of 0.01</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Corbel 2012</td>
<td>52/61</td>
<td>39/46</td>
<td>1.01 [ 0.86, 1.18 ]</td>
<td>100.0 %</td>
<td>1.01 [ 0.86, 1.18 ]</td>
</tr>
<tr>
<td><strong>Subtotal (95% CI)</strong></td>
<td>61</td>
<td>46</td>
<td>100.0 %</td>
<td>1.01 [ 0.86, 1.18 ]</td>
<td></td>
</tr>
<tr>
<td>Total events: 52 (IRS + ITNs), 39 (ITNs only)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heterogeneity: not applicable</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect: Z = 0.07 (P = 0.95)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 Sensitivity analysis with an estimated ICC of 0.05</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Corbel 2012</td>
<td>41/48</td>
<td>31/36</td>
<td>0.99 [ 0.83, 1.18 ]</td>
<td>100.0 %</td>
<td>0.99 [ 0.83, 1.18 ]</td>
</tr>
<tr>
<td><strong>Subtotal (95% CI)</strong></td>
<td>48</td>
<td>36</td>
<td>100.0 %</td>
<td>0.99 [ 0.83, 1.18 ]</td>
<td></td>
</tr>
<tr>
<td>Total events: 41 (IRS + ITNs), 31 (ITNs only)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heterogeneity: not applicable</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect: Z = 0.09 (P = 0.93)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3 Sensitivity analysis with an estimated ICC of 0.1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Corbel 2012</td>
<td>33/38</td>
<td>25/29</td>
<td>1.01 [ 0.83, 1.22 ]</td>
<td>100.0 %</td>
<td>1.01 [ 0.83, 1.22 ]</td>
</tr>
<tr>
<td><strong>Subtotal (95% CI)</strong></td>
<td>38</td>
<td>29</td>
<td>100.0 %</td>
<td>1.01 [ 0.83, 1.22 ]</td>
<td></td>
</tr>
<tr>
<td>Total events: 33 (IRS + ITNs), 25 (ITNs only)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heterogeneity: not applicable</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect: Z = 0.08 (P = 0.94)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>0.01</th>
<th>0.1</th>
<th>1</th>
<th>10</th>
<th>100</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Favours IRS + ITNs</td>
<td>Favours ITNs only</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## Analysis 2.1. Comparison 2 Pyrethroid-like indoor residual spraying (IRS) plus insecticide-treated nets (ITNs) versus ITNs alone, Outcome 1 Malaria incidence.

Review: Indoor residual spraying for preventing malaria in communities using insecticide-treated nets

Comparison: 2 Pyrethroid-like indoor residual spraying (IRS) plus insecticide-treated nets (ITNs) versus ITNs alone

Outcome: 1 Malaria incidence

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>log [Rate ratio] (SE)</th>
<th>Rate ratio</th>
<th>Weight</th>
<th>Rate ratio (SE)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kafy 2017 (1)</td>
<td>0 (0.5213)</td>
<td>7.9 %</td>
<td>1.00 [ 0.36, 2.78 ]</td>
<td></td>
</tr>
<tr>
<td>Pinder 2015</td>
<td>0.077 (0.1531)</td>
<td>92.1 %</td>
<td>1.08 [ 0.80, 1.46 ]</td>
<td></td>
</tr>
<tr>
<td><strong>Total (95% CI)</strong></td>
<td><strong>---</strong></td>
<td><strong>100.0 %</strong></td>
<td><strong>1.07 [ 0.80, 1.43 ]</strong></td>
<td></td>
</tr>
</tbody>
</table>

Heterogeneity: $\tau^2 = 0.0; \ Chi^2 = 0.02, df = 1 (P = 0.89); I^2 = 0.0$

Test for overall effect: $Z = 0.48 (P = 0.63)$

Test for subgroup differences: Not applicable

(1) IRS with deltamethrin (year 1)

## Analysis 2.2. Comparison 2 Pyrethroid-like indoor residual spraying (IRS) plus insecticide-treated nets (ITNs) versus ITNs alone, Outcome 2 Malaria parasite prevalence.

Review: Indoor residual spraying for preventing malaria in communities using insecticide-treated nets

Comparison: 2 Pyrethroid-like indoor residual spraying (IRS) plus insecticide-treated nets (ITNs) versus ITNs alone

Outcome: 2 Malaria parasite prevalence

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>log [Risk Ratio] (SE)</th>
<th>Risk Ratio</th>
<th>Weight</th>
<th>Risk Ratio (SE)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kafy 2017 (1)</td>
<td>0.6719 (0.4203)</td>
<td>9.7 %</td>
<td>1.96 [ 0.86, 4.46 ]</td>
<td></td>
</tr>
<tr>
<td>Keating 2011</td>
<td>0.1476 (0.5413)</td>
<td>5.9 %</td>
<td>1.16 [ 0.40, 3.35 ]</td>
<td></td>
</tr>
<tr>
<td>Pinder 2015 (2)</td>
<td>-0.0879 (0.1792)</td>
<td>47.6 %</td>
<td>0.92 [ 0.64, 1.30 ]</td>
<td></td>
</tr>
<tr>
<td>Pinder 2015 (3)</td>
<td>0.2013 (0.2075)</td>
<td>36.8 %</td>
<td>1.22 [ 0.81, 1.84 ]</td>
<td></td>
</tr>
<tr>
<td><strong>Total (95% CI)</strong></td>
<td><strong>---</strong></td>
<td><strong>100.0 %</strong></td>
<td><strong>1.11 [ 0.86, 1.44 ]</strong></td>
<td></td>
</tr>
</tbody>
</table>

Heterogeneity: $\tau^2 = 0.01; \ Chi^2 = 3.20, df = 3 (P = 0.36); I^2 = 6$

Test for overall effect: $Z = 0.80 (P = 0.42)$

Test for subgroup differences: Not applicable
Analysis 2.3. Comparison 2 Pyrethroid-like indoor residual spraying (IRS) plus insecticide-treated nets (ITNs) versus ITNs alone, Outcome 3 Anaemia prevalence.

Review: Indoor residual spraying for preventing malaria in communities using insecticide-treated nets

Comparison: 2 Pyrethroid-like indoor residual spraying (IRS) plus insecticide-treated nets (ITNs) versus ITNs alone

Outcome: 3 Anaemia prevalence

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>log [Risk Ratio] (SE)</th>
<th>Risk Ratio IV(Random,95% CI)</th>
<th>Weight</th>
<th>Risk Ratio IV(Random,95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pinder 2015 (1)</td>
<td>0.046 (0.1566)</td>
<td>1</td>
<td>54.1 %</td>
<td>1.05 [ 0.77, 1.42 ]</td>
</tr>
<tr>
<td>Pinder 2015 (2)</td>
<td>0.1887 (0.1699)</td>
<td>1</td>
<td>45.9 %</td>
<td>1.21 [ 0.87, 1.68 ]</td>
</tr>
</tbody>
</table>

Total (95% CI)

Heterogeneity: $\tau^2 = 0.0$; $\chi^2 = 0.38$, df = 1 ($P = 0.54$); $I^2 = 0.0$

Test for overall effect: $Z = 0.97$ ($P = 0.33$)

Test for subgroup differences: Not applicable

ADDITIONAL TABLES

Table 1. WHO-recommended insecticides for IRS against malaria vectors

<table>
<thead>
<tr>
<th>Insecticides and formulations</th>
<th>Dosage (g AI/m²)</th>
</tr>
</thead>
<tbody>
<tr>
<td>DDT WP</td>
<td>1-2</td>
</tr>
<tr>
<td>Malathion WP</td>
<td>2</td>
</tr>
<tr>
<td>Fenitrothion WP</td>
<td>2</td>
</tr>
</tbody>
</table>
Table 1. WHO-recommended insecticides for IRS against malaria vectors (Continued)

<table>
<thead>
<tr>
<th>Active Ingredient</th>
<th>WHO-recommended Concentration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pirimiphos-methyl WP, EC</td>
<td>1-2</td>
</tr>
<tr>
<td>Pirimiphos-methyl CS</td>
<td>1</td>
</tr>
<tr>
<td>Bendiocarb WP, WP-SB</td>
<td>0.1-0.4</td>
</tr>
<tr>
<td>Propoxur WP</td>
<td>1-2</td>
</tr>
<tr>
<td>Alpha-cypermethrin WP, SC, WG-SB</td>
<td>0.02-0.03</td>
</tr>
<tr>
<td>Bifenthrin WP</td>
<td>0.025-0.05</td>
</tr>
<tr>
<td>Cyfluthrin WP</td>
<td>0.02-0.05</td>
</tr>
<tr>
<td>Deltamethrin WP, WG, WG-SB, SC-PE</td>
<td>0.02-0.025</td>
</tr>
<tr>
<td>Etofenprox WP</td>
<td>0.1-0.3</td>
</tr>
<tr>
<td>Lambda-cyhalothrin WP, CS</td>
<td>0.02-0.03</td>
</tr>
</tbody>
</table>


Table 2. WHO-recommended long-lasting insecticidal nets

<table>
<thead>
<tr>
<th>Product name</th>
<th>Product type</th>
<th>Status of WHO recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>DawaPlus 2.0</td>
<td>Deltamethrin coated on polyester</td>
<td>Interim</td>
</tr>
<tr>
<td>Duranet</td>
<td>Alpha-cypermethrin incorporated into polyethylene</td>
<td>Full</td>
</tr>
<tr>
<td>Interceptor</td>
<td>Alpha-cypermethrin coated on polyester</td>
<td>Full</td>
</tr>
<tr>
<td>LifeNet</td>
<td>Deltamethrin incorporated into polypropylene</td>
<td>Interim</td>
</tr>
<tr>
<td>MAGNet</td>
<td>Alpha-cypermethrin incorporated into polyethylene</td>
<td>Full</td>
</tr>
<tr>
<td>MiraNet</td>
<td>Alpha-cypermethrin incorporated into polyethylene</td>
<td>Interim</td>
</tr>
<tr>
<td>Olyset Net</td>
<td>Permethrin incorporated into polyethylene</td>
<td>Full</td>
</tr>
<tr>
<td>Olyset Plus</td>
<td>Permethrin and PBO incorporated into polyethylene</td>
<td>Interim</td>
</tr>
<tr>
<td>Panda Net 2.0</td>
<td>Deltamethrin incorporated into polyethylene</td>
<td>Interim</td>
</tr>
</tbody>
</table>
### Table 2. WHO-recommended long-lasting insecticidal nets (Continued)

<table>
<thead>
<tr>
<th>Net</th>
<th>Description</th>
<th>Availability</th>
</tr>
</thead>
<tbody>
<tr>
<td>PermaNet 2.0</td>
<td>Deltamethrin coated on polyester</td>
<td>Full</td>
</tr>
<tr>
<td>PermaNet 3.0</td>
<td>Combination of deltamethrin coated on polyester with strengthened border (side panels), and deltamethrin and PBO incorporated into polyethylene (roof)</td>
<td>Interim</td>
</tr>
<tr>
<td>Royal Sentry</td>
<td>Alpha-cypermethrin incorporated into polyethylene</td>
<td>Full</td>
</tr>
<tr>
<td>SafeNet</td>
<td>Alpha-cypermethrin coated on polyester</td>
<td>Full</td>
</tr>
<tr>
<td>Veeralin</td>
<td>Alpha-cypermethrin and PBO incorporated into polyethylene</td>
<td>Interim</td>
</tr>
<tr>
<td>Yahe</td>
<td>Deltamethrin coated on polyester</td>
<td>Interim</td>
</tr>
<tr>
<td>Yorkool</td>
<td>Deltamethrin coated on polyester</td>
<td>Full</td>
</tr>
</tbody>
</table>

Abbreviations: LLIN: long-lasting insecticidal nets; PBO: piperonyl butoxide; WHO: World Health Organization. Adapted from [WHO 2014b](https://www.who.int/).

### Table 3. WHO-recommended insecticide products for treatment of mosquito nets for malaria vector control

<table>
<thead>
<tr>
<th>Insecticide</th>
<th>Formulation</th>
<th>Dosage (mg AI/m² of netting)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alpha-cypermethrin</td>
<td>SC 10%</td>
<td>20-40</td>
</tr>
<tr>
<td>Cyfluthrin</td>
<td>EW 5%</td>
<td>50</td>
</tr>
<tr>
<td>Deltamethrin</td>
<td>SC 1%; WT 25%; and WT 25% + binder</td>
<td>15-25</td>
</tr>
<tr>
<td>Etofenprox</td>
<td>EW 10%</td>
<td>200</td>
</tr>
<tr>
<td>Lambda-cyhalothrin</td>
<td>CS 2.5%</td>
<td>10-15</td>
</tr>
<tr>
<td>Permethrin</td>
<td>EC 10%</td>
<td>200-500</td>
</tr>
<tr>
<td>ICON MAXX (long-lasting lambda-cyhalothrin formulation)</td>
<td>CS 10% + binder</td>
<td>50-83</td>
</tr>
</tbody>
</table>

Abbreviations: AI: active ingredient; EC: emulsifiable concentrate; EW: emulsion, oil in water; CS: capsule suspension; SC: suspension concentrate; WT: water dispersible tablet; WHO: World Health Organization. Adapted from [WHO 2014c](https://www.who.int/).
## Table 4. Characteristics of indoor residual spraying

<table>
<thead>
<tr>
<th>Study</th>
<th>Active ingredient, formulation, and dose</th>
<th>Frequency of application</th>
<th>Coverage</th>
<th>Who carried out the spraying</th>
<th>Vector species</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Comparison 1: IRS using non-pyrethroid-like insecticides plus ITNs versus ITNs alone</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Corbel 2012</td>
<td>Bendiocarb 80% wettable powder (FICAM 80, Bayer) 400 mg/m²</td>
<td>Every 8 months, June 2008 to December 2009</td>
<td>Aimed for 80%</td>
<td>Unreported</td>
<td><em>An gambiae s.l.</em> and <em>An funestus s.l.</em></td>
</tr>
<tr>
<td>Kafy 2017 (Years 2 and 3)</td>
<td>Bendiocarb 80% wettable powder (FICAM 80, Bayer) 200 mg/m²</td>
<td>Twice a year, August and late December, 2013 and 2014</td>
<td>2013: 82% 2014: 83%</td>
<td>Unreported</td>
<td><em>An gambiae s.l.</em> and <em>An funestus s.l.</em></td>
</tr>
<tr>
<td>Protopopoff 2018</td>
<td>Pirimiphos-methyl 30% capsule suspension (Actellic 300CS) 1 g active ingredient/m²</td>
<td>Once, February 2015</td>
<td>Standard ITN arm: 0.5% (95% CI 0.1 to 2.0) Standard ITN + IRS arm: 94% (95% CI 92 to 96) Pyrethroid-PBO net arm: 4% (95% CI 0.5 to 29) Pyrethroid-PBO net + IRS arm: 94% (95% CI 87 to 97) Buffer size between clusters: minimum outer buffer zone of 300 m. Only the inner core area was used for the measurement of study outcomes</td>
<td>Unreported</td>
<td><em>An gambiae s.s.</em>, <em>An arabiensis</em> and <em>An funestus</em></td>
</tr>
<tr>
<td>West 2014</td>
<td>Bendiocarb 80% wettable powder (FICAM 80, Bayer) 400mg/m²</td>
<td>Twice December 2011 to January 2012 and April 2012 to May 2012</td>
<td>Aimed for 80% (actual coverage was 89.3-92.1%)</td>
<td>RTI International on behalf of PMI</td>
<td><em>An gambiae s.s.</em> and <em>An arabiensis</em></td>
</tr>
<tr>
<td><strong>Comparison 2: IRS using pyrethroid-like insecticides plus ITNs versus ITNs alone</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kafy 2017 (Year 1)</td>
<td>Deltamethrin (25 mg/m², formulation not reported, Chema Industries)</td>
<td>Twice, in August and late December 2012</td>
<td>99%</td>
<td>Unreported</td>
<td><em>An gambiae s.l.</em> and <em>An funestus s.l.</em></td>
</tr>
</tbody>
</table>
Table 4. Characteristics of indoor residual spraying (Continued)

<table>
<thead>
<tr>
<th>Study</th>
<th>Time period</th>
<th>Coverage</th>
<th>Insecticide</th>
<th>Remarks</th>
<th>Species</th>
</tr>
</thead>
<tbody>
<tr>
<td>Keating 2011</td>
<td>June-July 2009</td>
<td>Aimed for 80% (84.8% of households sampled sprayed within 12 months)</td>
<td>DDT wettable powder 1-2 g active ingredient/m²</td>
<td>Unreported</td>
<td>An arabiensis and An gambiae s.s.</td>
</tr>
<tr>
<td>Pinder 2015</td>
<td>Once per year, July 2010 and July-August 2011</td>
<td>Aimed for 80% (actual coverage was 83-86%)</td>
<td>DDT 75% wettable powder (Hindustan Insecticides) 2 g active ingredient/m²</td>
<td>Operators from the Gambian National Malaria Control Programme and team leaders from the regional health team</td>
<td>An gambiae s.l.</td>
</tr>
</tbody>
</table>

Abbreviations: CI: confidence interval; DDT: dichloro-diphenyl-trichloroethane; IRS: indoor residual spraying; ITN: insecticide-treated net; PBO: piperonyl butoxide.

Table 5. ITN coverage and compliance

<table>
<thead>
<tr>
<th>Study</th>
<th>Arm</th>
<th>Coverage measure</th>
<th>Coverage: mean (95% CI) unless stated otherwise</th>
<th>Compliance measure</th>
<th>Compliance</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Comparison 1: IRS using non-pyrethroid-like insecticides plus ITNs versus ITNs alone</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Corbel 2012</td>
<td>Control</td>
<td>Total number of hung nets relative to the total number of sleeping units</td>
<td>38% (36 to 41)</td>
<td>Low</td>
<td>Mean (95% CI): 43% (40 to 45)</td>
</tr>
<tr>
<td></td>
<td>Intervention</td>
<td>45% (43 to 48)</td>
<td>Low</td>
<td></td>
<td>Low</td>
</tr>
<tr>
<td>Kafy 2017</td>
<td>Control</td>
<td>An annual intervention assessment survey on household net ownership</td>
<td>2013: 82.1% 2014: 98.6%</td>
<td>High</td>
<td>Mean (95% CI): 2013: 74% 2014: 82%</td>
</tr>
<tr>
<td></td>
<td>Intervention</td>
<td></td>
<td>Defined as the proportion of affirmative responses to the question “Did this child sleep under an ITN last night?”</td>
<td>High</td>
<td>2013: 75% 2014: 82%</td>
</tr>
<tr>
<td>Protopopoff 2018</td>
<td>Standard ITNs</td>
<td>Household owning ≥ 1 LLIN (study LLIN or any other LLIN)</td>
<td>At 9 months’ postintervention: 97% (95% CI 93 to 99)</td>
<td>Residents declaring using an ITN the previous night (study ITN or any other ITN)</td>
<td>At 9 months’ postintervention: 80% (95% CI 75 to 85)</td>
</tr>
</tbody>
</table>

Indoor residual spraying for preventing malaria in communities using insecticide-treated nets (Review) Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.
<table>
<thead>
<tr>
<th>Table 5. ITN coverage and compliance (Continued)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Month</strong></td>
</tr>
<tr>
<td><strong>West 2014</strong></td>
</tr>
<tr>
<td>February-March:</td>
</tr>
<tr>
<td>June-July:</td>
</tr>
<tr>
<td>October-December:</td>
</tr>
<tr>
<td><strong>Intervention</strong></td>
</tr>
<tr>
<td>February-March:</td>
</tr>
<tr>
<td>June-July:</td>
</tr>
<tr>
<td>October-December:</td>
</tr>
</tbody>
</table>

**Comparison 2: IRS using pyrethroid-like insecticides plus ITNs versus ITNs alone**

<table>
<thead>
<tr>
<th><strong>Kafy 2017</strong></th>
<th>Control</th>
<th>An annual intervention assessment survey on household net ownership</th>
<th>Defined as the proportion of affirmative responses to the question “Did this child sleep under an ITN last night?”</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Intervention</strong></td>
<td>99.6%</td>
<td>High</td>
<td>79%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Keating 2011</strong></th>
<th>Control</th>
<th>Measured as people living in household owning ≥ 1 ITN</th>
<th>Measured as people using ITN in the previous night</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Intervention</strong></td>
<td>72% (70.2 to 73.7)</td>
<td>Moderate</td>
<td>Mean (95% CI): 46.2 (43.9 to 48.6)</td>
</tr>
</tbody>
</table>
Table 5. ITN coverage and compliance (Continued)

<table>
<thead>
<tr>
<th>Intervention</th>
<th>75.8% (74.2 to 77.4) Mod</th>
<th>Mean (95% CI): 50.7% (48.6 to 52.8) Mod</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pinder 2015 Control</td>
<td>Not reported</td>
<td>Not reported</td>
</tr>
<tr>
<td>Intervention</td>
<td>Mean average across all clusters: 2011: 92% 2012: 96% High</td>
<td></td>
</tr>
<tr>
<td>Mean average across all clusters: 2011: 89% 2012: 93% High</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: CI: confidence interval; IRS: indoor residual spraying; ITN: insecticide-treated net; LLIN: long-lasting insecticidal mosquito net.

*Coverage and compliance cutoffs (low, moderate, and high) prespecified in protocol.*

Table 6. Entomological inoculation rate results

<table>
<thead>
<tr>
<th>Trial</th>
<th>Methods of EIR measurement</th>
<th>Comparison</th>
<th>Mean EIR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>IRS + ITNs</td>
<td>ITNs alone</td>
<td>IRS + ITNs</td>
</tr>
<tr>
<td><strong>Comparison 1: IRS using non-pyrethroid-like insecticides + ITNs versus ITNs alone</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Corbel 2012</td>
<td>Mean number of infected bites per man per year (estimated from the number of anopheline vectors caught using human landing catches and the proportion of anopheline vectors infective)</td>
<td>IRS with standard ITN versus standard ITN alone</td>
<td>7.3 (3.8 to 14.2)</td>
</tr>
<tr>
<td>Protopopoff 2018</td>
<td>Mean number of infected bites per household per night (the number of infective anopheline vectors caught using light traps in 1 night per month was used as a proxy for this)</td>
<td>IRS with standard ITN versus standard ITN alone</td>
<td>0.05 (n = 413)</td>
</tr>
</tbody>
</table>
Table 6. Entomological inoculation rate results  
(Continued)

<table>
<thead>
<tr>
<th>Trial</th>
<th>Assessment method</th>
<th>Comparison</th>
<th>Reported results</th>
<th>Effect size (95% CIs)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>IRS with pyrethroid-PBO net versus pyrethroid-PBO net alone</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>West 2014</td>
<td>Mean number of infected bites per household per month (estimated from the number of infective anopheline vectors caught using light traps in 1 night)</td>
<td>IRS with standard ITN versus standard ITN alone</td>
<td>1.3 (0.4 to 4.4)</td>
<td>1.1 (0.4 to 2.8)</td>
</tr>
</tbody>
</table>

Comparison 2: IRS using pyrethroid-like insecticides + ITNs versus ITNs alone

<table>
<thead>
<tr>
<th>Trial</th>
<th>Assessment method</th>
<th>Comparison</th>
<th>Reported results</th>
<th>Effect size (95% CIs)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>IRS with standard ITN versus standard ITN alone: 2010</td>
<td></td>
<td>1.08 (0.16 to 4.02)</td>
<td>2.44 (0.69 to 6.39)</td>
</tr>
<tr>
<td></td>
<td>IRS with standard ITN versus standard ITN alone: 2011</td>
<td></td>
<td>0.29 (0.00 to 2.66)</td>
<td>1.45 (0.15 to 5.69)</td>
</tr>
</tbody>
</table>

Abbreviations: CI: confidence interval; EIR: entomological inoculation rate; IRS: indoor residual spraying; ITNs: insecticide-treated nets; n: number of participants; PBO: piperonyl butoxide.

Table 7. Sporozoite rate results

<table>
<thead>
<tr>
<th>Trial</th>
<th>Assessment method</th>
<th>Comparison</th>
<th>Reported results</th>
<th>Effect size (95% CIs)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>IRS + ITNs versus ITNs alone</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| Comparison 1: IRS using non-pyrethroid-like insecticides plus ITNs versus ITNs alone
| Corbel 2012    | % of *An. gambiae* s.l. caught from human landing catches with sporozoites (ELISA) | IRS with standard ITN versus standard ITN alone | 3.22% (95% CI 1.76 to 4.68) | 2.83% (95% CI 1.69 to 3.97) |
| Protopopoff 2018 | % of *An. gambiae* s.l. caught from light traps with sporozoites (ELISA) | IRS with standard ITN versus standard ITN alone | 0.4% (1/269) | 2.8% (19/683) |

Indoor residual spraying for preventing malaria in communities using insecticide-treated nets (Review)  
Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.
### Table 7. Sporozoite rate results

(Continued)

<table>
<thead>
<tr>
<th>Comparison 1: IRS with pyrethroid-PBO net versus pyrethroid-PBO net alone</th>
<th>IRS with pyrethroid-PBO net versus pyrethroid-PBO net alone</th>
<th>0.0% (0/343)</th>
<th>0.7% (2/305)</th>
</tr>
</thead>
<tbody>
<tr>
<td>West 2014</td>
<td>IRS with standard ITN versus standard ITN alone</td>
<td>1.8% (95% CI 0.5 to 6.2; n = 717)</td>
<td>2.5% (95% CI 2.1 to 3.1; n = 3059)</td>
</tr>
</tbody>
</table>

### Comparison 2: IRS with standard ITN versus standard ITN alone

<table>
<thead>
<tr>
<th>Study</th>
<th>Method of adult mosquito density measurement</th>
<th>Comparison</th>
<th>Reported results Mean (95% CIs)</th>
<th>Effect size (95% CIs)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pinder 2015</td>
<td>% of <em>An. gambiae s.l.</em> caught from light traps with sporozoites (ELISA)</td>
<td>IRS with standard ITN versus standard ITN alone: 2010</td>
<td>0.19% (4/2131)</td>
<td>0.32% (9/2829)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>IRS with standard ITN versus standard ITN alone: 2011</td>
<td>0.65% (5/773)</td>
<td>0.09% (1/1131)</td>
</tr>
</tbody>
</table>

Abbreviations: CI: confidence interval; ELISA: enzyme-linked immunosorbent assay; IRS: indoor residual spraying; ITN: insecticide-treated net; MD: mean difference; OR: odds ratio; PBO: piperonyl butoxide; RR: risk ratio.

*Not adjusted for clustering.*

### Table 8. Adult mosquito density results

<table>
<thead>
<tr>
<th>Trial</th>
<th>Methods of adult mosquito density measurement</th>
<th>Comparison</th>
<th>Reported results Mean (95% CIs)</th>
<th>Effect size (95% CIs)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Corbel 2012</td>
<td>Mean number of bites per man per year from human landing catches (16 person-nights per village (total 28 villages divided evenly into 4 arms) per survey (total 8 surveys))</td>
<td>IRS with standard ITN versus standard ITN alone</td>
<td>228 (149 to 348; n = 896)</td>
<td>331 (218 to 504; n = 896)</td>
</tr>
</tbody>
</table>
Table 8.  Adult mosquito density results  

(Continued)

<table>
<thead>
<tr>
<th>Study</th>
<th>Methodology</th>
<th>IRS with standard ITN versus standard ITN alone</th>
<th>IRS with pyrethroid-PBO net versus pyrethroid-PBO net alone</th>
<th>Rate ratio (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Protopopoff 2018</td>
<td>Mean number of vectors caught in light traps per night per household (7 randomly selected houses per cluster (total 48 clusters divided evenly into 4 arms) for 1 night per month (total 8 months))</td>
<td>2.37 (n = 425)</td>
<td>1.85 (n = 493)</td>
<td>Not reported</td>
</tr>
<tr>
<td></td>
<td>IRS with pyrethroid-PBO net versus pyrethroid-PBO net alone</td>
<td>2.83 (n = 471)</td>
<td>1.84 (n = 468)</td>
<td></td>
</tr>
<tr>
<td>West 2014</td>
<td>Mean number of <em>An. gambiae s.l.</em> per house per night (8 randomly selected houses per cluster (total 40 clusters divided evenly into 2 arms) for 1 night per month (total 21 months))</td>
<td>0.4 (0.1 to 1.4; n = 1893)</td>
<td>1.7 (0.5 to 6.4; n = 1892)</td>
<td>Rate ratio 0.23 (0.04 to 1.44)</td>
</tr>
<tr>
<td></td>
<td>IRS with standard ITN versus standard ITN alone</td>
<td>1.7 (0.5 to 6.4; n = 1892)</td>
<td>1.7 (0.5 to 6.4; n = 1892)</td>
<td></td>
</tr>
</tbody>
</table>

Comparison 2: IRS using pyrethroid-like insecticides + ITNs versus ITNs alone

<table>
<thead>
<tr>
<th>Study</th>
<th>Methodology</th>
<th>IRS with standard ITN versus standard ITN alone</th>
<th>IRS with standard ITN versus standard ITN alone: 2010 light traps</th>
<th>IRS with standard ITN versus standard ITN alone: 2010 exit traps</th>
<th>IRS with standard ITN versus standard ITN alone: 2011 light traps</th>
<th>MD (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pinder 2015</td>
<td>Mean number of <em>An. gambiae s.l.</em> per trap per night (6 sentinel rooms in 32 clusters)</td>
<td>3.70 (2.03 to 5.37)</td>
<td>4.92 (3.05 to 6.79)</td>
<td>0.40 (-0.15 to 0.66)</td>
<td>0.54 (0.18 to 0.89)</td>
<td>MD -1.22 (-3.58 to 1.14)</td>
</tr>
<tr>
<td></td>
<td>IRS with standard ITN versus standard ITN alone: 2010 exit traps</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>IRS with standard ITN versus standard ITN alone: 2011 light traps</td>
<td>1.27 (0.39 to 2.15)</td>
<td>1.96 (0.69 to 3.24)</td>
<td></td>
<td></td>
<td>MD -0.69 (-2.15 to 0.77)</td>
</tr>
<tr>
<td></td>
<td>IRS with standard ITN versus standard ITN alone: 2011 exit traps</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Table 8. Adult mosquito density results  (Continued)

<table>
<thead>
<tr>
<th></th>
<th>IRS with standard ITN versus standard ITN alone: 2011 exit traps</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>0.06</td>
<td>0.46</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(0.01 to 0.10)</td>
<td>(-0.23 to 1.15)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>MD -0.40</td>
<td>(-1.05 to 0.25)</td>
</tr>
</tbody>
</table>

Abbreviations: CI: confidence interval; IRS: indoor residual spraying; ITNs: insecticide-treated nets; MD: mean difference; PBO: piperonyl butoxide.

APPENDICES

Appendix 1. Search strategies

<table>
<thead>
<tr>
<th>PubMed search set</th>
<th>Search terms</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Malaria [Mesh], Title/Abstract</td>
</tr>
<tr>
<td>2</td>
<td>Mosquito* Title/Abstract</td>
</tr>
<tr>
<td>3</td>
<td>&quot;Anopheles&quot;[Mesh]</td>
</tr>
<tr>
<td>4</td>
<td>1 or 2 or 3</td>
</tr>
<tr>
<td>5</td>
<td>&quot;indoor residual spraying&quot; or IRS* Title/Abstract</td>
</tr>
<tr>
<td>6</td>
<td>&quot;house spray*&quot; Title/Abstract</td>
</tr>
<tr>
<td>7</td>
<td>( &quot;Insecticides/administration and dosage&quot;[Mesh] or &quot;Insecticides/supply and distribution&quot;[Mesh] or &quot;Insecticides/therapeutic use&quot;[Mesh] ) or &quot;Pyrethrins&quot;[Mesh]</td>
</tr>
<tr>
<td>8</td>
<td>malathion or fenitrothion or pirimiphos-methyl or bendiocarb or propoxur or alpha-cypermethrin or bifenthrin or cyfluthrin or deltamethrin or etofenprox or lambda-cyhalothrin or DDT Title/Abstract</td>
</tr>
<tr>
<td>9</td>
<td>&quot;insecticide-treated bednet*&quot; or insecticide-treated net*&quot; or &quot;Long-lasting insecticidal net*&quot; or LLIN* or ITN* or LN<em>or &quot;bed net</em>&quot; or &quot;long-lasting net*&quot; Title/Abstract</td>
</tr>
<tr>
<td>10</td>
<td>&quot;Insecticide-Treated Bednets&quot; [Mesh]</td>
</tr>
<tr>
<td>11</td>
<td>(&quot;Mosquito Control/instrumentation&quot;[Mesh] OR &quot;Mosquito Control/methods&quot;[Mesh])</td>
</tr>
</tbody>
</table>
(Continued)

12 5 or 6 or 7 or 8
13 9 or 10 or 11
14 4 and 12 and 13
15 “Randomized Controlled Trial” [Publication Type] OR “Controlled Clinical Trial” [Publication Type]
16 single-blind* or double-blind* Title/Abstract
17 randomized or placebo or trial or groups or randomly Title/Abstract
18 “before and after” Title/Abstract
19 “Epidemiologic Studies”[Mesh]
20 “time series” Title/Abstract
21 20 OR 19 OR 18 OR 17 OR 16 OR 15
22 21 AND 14

Embase
1 malaria/ or malaria.mp.
2 Anopheles/ or anopheles.mp.
3 mosquito*.mp. or mosquito/
4 1 or 2 or 3
5 indoor residual spraying.mp. or indoor residual spraying/
6 indoor residual spray.mp.
7 house spray.mp.
8 house spraying.mp.
9 IRS.ab. or IRS.ti.
10 (malathion or fenitrothion or pirimiphos-methyl or bendiocarb or propoxur or alpha-cypermethrin or bifenthrin or cyfluthrin or deltamethrin or etofenprox or lambda-cyhalothrin or DDT).mp.
11 insecticide/ct, ad, cb, cm, dt [Clinical Trial, Drug Administration, Drug Combination, Drug Comparison, Drug Therapy]
12 pyrethroid/ct, ad, cb, cm, dt [Clinical Trial, Drug Administration, Drug Combination, Drug Comparison, Drug Therapy]
13 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12
14 4 and 13
15 (Net* or bednet* or ITN* or LLIN* or “Insecticide-Treated Bednet” or “Insecticide-Treated net”).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word]
16 bed net/
17 insecticide treated net/
18 15 or 16 or 17
19 14 and 18
20 randomized controlled trial/ or controlled clinical trial/
21 (randomized or randomised or placebo or double-blind* or single-blind*).mp.
22 epidemiology/
LILACS
(tw:(indoor residual spraying OR irs OR house spraying)) AND (tw:(bednets OR nets OR itn)) AND (tw:(malaria OR mosquito OR anopheles)) AND (tw:(randomized OR controlled OR trial OR comparison OR compared))

Cochrane Central Register of Controlled Trials
Issue 3 of 12, April 2019
ID Search Hits
#1 MeSH descriptor: [Malaria] explode all trees
#2 malaria:ti,ab,kw (Word variations have been searched)
#3 anopheles
#4 MeSH descriptor: [Anopheles] explode all trees
#5 mosquito*
#6 #1 or #2 or #3 or #4 or #5
#7 "indoor residual spray"
#8 "indoor residual spraying"
#9 "house spray"*
#10 IRS
#11 malathion or fenitrothion or pirimiphos-methyl or bendiocarb or propoxur or alpha-cypermethrin or bifenthrin or cyfluthrin or deltamethrin or etofenprox or lambda-cyhalothrin or DDT
#12 MeSH descriptor: [Insecticides] explode all trees and with qualifier(s): [Administration & dosage - AD, Supply & distribution - SD, Therapeutic use - TU]
#13 MeSH descriptor: [Pyrethrins] explode all trees and with qualifier(s): [Administration & dosage - AD, Supply & distribution - SD, Therapeutic use - TU]
#14 #7 or #8 or #9 or #10 or #11 or #12 or #13
#15 Net* or bednet* or ITN* or LLIN* or "Insecticide-Treated Bednet*" or "Insecticide-Treated net*"
#16 MeSH descriptor: [Insecticide-Treated Bednets] explode all trees
#17 #15 or #16
#18 #6 and #14 and #17

CONTRIBUTIONS OF AUTHORS
All authors contributed to the protocol design, wrote the protocol, and approved the final version.
LC and JP screened articles, extracted data from the included studies, and conducted the analysis.
PJG acted as arbitrator.
All authors sought to interpret the data, and prepared and interpreted the GRADE summaries.
LC and JP wrote the full text and PG edit modified this. All authors read and approved the final manuscript.
DECLARATIONS OF INTEREST

LC: none.
JP: none.
PG is the Director of READ-It, a DFID-funded research programme that aims to increase the number of decisions in low- and middle-income countries based on reliable evidence.

SOURCES OF SUPPORT

Internal sources
- Liverpool School of Tropical Medicine, UK.

External sources
- Department for International Development, UK.
  Project number: 300342-104
- World Health Organization (WHO), Switzerland.
  WHO Global Malaria Programme Agreement for Performance of Work (APW) Grant 2017 (number 709319)
- Partnership for Increasing the Impact of Vector Control (PIIVeC), UK.
  Provided support to LC. PIIVeC is funded by the Medical Research Council of the UK (grant number MR/P027873/1) through the Global Challenges Research Fund.

DIFFERENCES BETWEEN PROTOCOL AND REVIEW

We amended the title from 'The combination of indoor residual spraying with insecticide-treated nets versus insecticide-treated nets alone for preventing malaria' to 'Indoor residual spraying for preventing malaria in communities using insecticide-treated nets'.

In the protocol, we initially limited the outcome of insecticide resistance to the specific insecticide used for IRS (Choi 2017). However, during the extraction process, it became apparent that resistance to pyrethroid insecticides was also an important outcome in trials using non-pyrethroid-like insecticides for IRS. Therefore, we extracted resistance outcome data for both classes of insecticide.

We also made changes to the way that we subgrouped trials. Initially, we intended to include all comparisons of IRS plus ITNs versus ITNs alone in one analysis, regardless of the target site of the insecticide used for IRS. However, we prespecified that we would subgroup the data by this target site to explore potential causes of heterogeneity. Following referee feedback, it became clear that the most important policy question was to assess the effectiveness of combining ITNs with a non-pyrethroid-like IRS. Therefore we decided not to conflate this analysis with that of the pyrethroid-like IRS interventions, and instead presented two separate comparisons.

We stated in the protocol that we would perform the following subgroup analyses to investigate heterogeneity:

- Use of LLINs/ITNs defined by individual use from the previous night:
  - high (80% to 100%);
  - moderate (50% to 79%);
  - low (less than 50%).
- Coverage of IRS:
  - high (80% to 100%);
  - moderate (50% to 79%).
• low (less than 50%).

• Seasonality of malaria:
  o perennial;
  o seasonal;
  o epidemic.

Due to few studies and lack of data surrounding certain subgroups, we were only able to perform the following subgroup analysis.

• Use of LLINs/ITNs defined by individual use from the previous night:
  o high (50% or more);
  o low (less than 50%).

Finally, we originally stated in the protocol that a P value less than 0.05 indicated statistically significant differences between subgroups but we have amended this to less than 0.1.